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SUMMARY 
Pancreatic stellate cells (PSCs) are generally quiescent in normal conditions, but during 
inflammation or cancer these cells are activated, differentiate to myofibroblast-like cells, 
proliferate, migrate and start secreting extracellular matrix protein, which are the main 
contributors to the stromal formation during the process of cancer. EP300 is an important 
transcription coactivator and plays an important role in the process of cell proliferation and 
differentiation. Thus, we hypothesize that targeting EP300 will affect the activation of PSCs 
and may influence the process of pancreatic cancer, especially for pancreatic ductal 
adenocarcinoma (PDAC). Transient specific small interfering RNA (SiRNA) knockdown of 
EP300 resulted in reduced expression of fibronectin (FN) and collagen I (Col-I) in activated 
PSCs. Stable knockdown of EP300 by CRISPR/Cas9 gRNA plasmid had the same effects. 
However, the migration of PSCs was increased. And we firstly showed that EP300 
manipulated cell migration through ERK pathway. Furthermore, EP300 down regulation in 
PSCs increased the proliferation effect PSCs had on pancreatic cancer cells and PSCs 
protected tumor cells from chemotherapy more. Together, the evidences draw the conclusion 
that EP300 is a tumor suppressor gene, its downregulation increases the migration of PSCs 
and PSCs becomes more supportive for pancreatic cancer cells, but that reduces the extra 
cellular matrix production of PSCs.  
High resistance to chemotherapy is a frustrating issue in treating pancreatic ductal 
adenocarcinoma. It is one reason for a 5-year survival rate of PDAC patients lower than 5%. 
In recent years, researcher showed that the tumor microenvironment might make a great 
contribution to the drug resistance of pancreatic cancer. PSCs are important cells that exist in 
the tumor stroma of pancreatic cancer. Gemcitabine is a nucleoside analog, which is currently 
used as the best standard treatment for pancreatic cancer patients. In the present study, I 
analyzed how PSCs will affect the drug resistance of different drug sensitive pancreatic 
cancer cell lines. My results for the first time showed that conditioned medium from PSCs 
promotes chemo-resistance of Bxpc-3 cells by up regulating RRM1 and RRM2, but has no 
influence on the drug sensitivity of Panc-1 and Miapaca-2 cells. In addition, I could show that 
factors that are <100kDa and produced by pancreatic stellate cells are responsible for the 
effects. These factors are heat insensitive, trypsin and proteinase K insensitive and cannot be 
degraded by nucleases either, but the exact factor has yet to be determined. 
 Zusammenfassung 
 V 
ZUSAMMENFASSUNG 
Pankreas Sternzellen (PSCs) befinden sich üblicherweise in einem ruhenden Zustand. 
Während einer Entzündung des Pankreas oder bei Auftreten von Krebs werden diese Zellen 
jedoch aktiviert. Sie differenzieren dann in Zellen, die sich durch myofibroblastäre 
Eigenschaften auszeichnen, proliferieren, Migration zeigen und beginnen, extrazelluläre 
Matrix-Proteine zu sezernieren. Sie leisten einen wesentlichen Beitrag zur Bildung des 
Stroma, das bei Pankreaskrebs und speziell dem duktalen Adenokarzinom des Pankreas 
(PDAC) stark ausgeprägt ist. Das Protein EP300 ist ein zentraler Co-Aktivator der 
Transkription und spielt eine wichtige Rolle im Prozess der Zellproliferation und 
Zelldifferenzierung. Deshalb hatten wir die Hypothese aufgestellt, dass eine Beeinflussung 
von EP300 auf die Aktivierung von PSCs und damit auf Pankreaskrebs einwirkt. Eine 
transiente Herunterregulierung von EP300 mittels spezifischer, kleiner, interferierender RNA 
(small interfering RNA; siRNA) Moleküle reduzierte die Expression von Fibronektin (FN) 
und Collagen I (Col-I) in aktivierten PSCs. Eine stabile Reduzierung der EP300 Expression 
mittels des CRISPR-Cas9 Systems zeigte den gleichen Effekt. Die Zellmigration wurde 
dagegen verstärkt. Ich konnte zeigen, dass der Mechanismus, mit dem EP300 die Migration 
beeinflusst, durch den ERK Stoffwechselweg erfolgt. Außerdem steigerte die Reduzierung der 
EP300 Menge in PSCs den Effekt auf die Zellproliferation in Pankreaskrebs, die von den 
PSCs ausgeht. Gleichzeitig schützten solch modifizierten PSCs den Tumor stärker vor 
Chemotherapie. In Kombination erlauben die Ergebnisse die Schlussfolgerung, dass EP300 
ein Tumorsuppressor-Gen darstellt. Eine reduzierte Expression führt zu mehr PSC Migration. 
Gleichzeitig unterstützen diese PSCs die Tumorzellen, während die Produktion der 
extrazellulären Matrix reduziert wird. 
 
Der hohe Grad an Resistenz gegenüber Chemotherapie ist eine der frustrierenden Facetten bei 
der Behandlung von duktalem Adenokarzinom des Pankreas (PDAC). Sie ist ein Grund, 
warum die 5-Jahres Überlebensrate mit etwa 5% der Patienten so gering ist. In den letzten 
Jahren konnte gezeigt werden, dass die Tumor-Mikroumgebung (tumor microenvironment) 
einen großen Beitrag zu dieser Resistenzausbildung leistet. PSCs sind eine wichtige 
Zellkomponente im Stroma von PDAC Tumorgeweben. Gemcitabin ist eine Nukleosid-
Analog, das zurzeit immer noch die Grundlage der Standardbehandlung von PDAC darstellt. 
In meiner Arbeit habe ich analysiert, wie PSCs für verschiedenen PDAC Zelllinien die 
Resistenz auf Chemotherapie beeinflussen. Meine Ergebnisse zeigen, dass Medium mit den 
sezernierten Molekülen (conditioned medium) von PSCs die Chemo-Resistenz der PDAC 
Zelllinie Bxpc-3 durch eine Regulation von RRM1 und RRM2 stärken. Im Gegensatz dazu 
hat es keinen Einfluss auf die Sensitivität der Zelllinien Panc-1 und Miapaca-2. Zusätzlich 
konnte ich zeigen, dass Faktoren einer Größe kleiner 100 kDa für den Effekt verantwortlich 
sind. Diese Faktoren konnten weder durch Hitze noch Verdau mit Trypsin und Proteinase K 
oder Nukleasen inaktiviert werden. 
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Part I:  Exploring the Functions of EP300 in Activated Pancreatic 
Stellate Cells 
1 Introduction 
1.1 Pancreas 
Pancreas is a glandular organ, located across the back of the abdomen, behind the stomach. It 
contains two types of glands: (1) Exocrine. The exocrine gland excretes various enzymes to 
digest different substances in food. (2) Endocrine. The endocrine gland secretes hormones 
into the blood, which controls the blood sugar levels throughout the day. These two functions 
are vital to the body’s survival [1]. 
1.1.1 Anatomy of the pancreas 
In humans, the pancreas weighs on average 80g and is about 15 to 20 cm long, which extends 
laterally and superiorly across the abdomen from the curve of the duodenum to the spleen. It 
composes of three regions. The head of the pancreas connects to the duodenum, which is the 
widest region of the organ. The body of the pancreas extends laterally toward the left. The 
tapered left side of the pancreas is referred as the tail region, which is near the spleen. As 
showed in Figure 1. 
The exocrine of the pancreas is composed of grape like cell clusters, which are called acini. 
When acinar cells are stimulated, they release enzyme-rich pancreatic juice into the ducts. 
Scattered through the sea of exocrine acini are small islands of endocrine cells, the islets of 
Langerhans. The hormones secreted by endocrine cells are important in glucose homeostasis. 
There are two main types of endocrine cells, alpha cells, which raise blood glucose levels, and 
beta cells, which lower blood glucose levels [2].  
1.1.2 Regulation of the pancreas 
There are two systems which can regulate the function of the pancreas: the autonomic nervous 
system (ANS) and the endocrine system. The sympathetic and the parasympathetic division in 
the ANS control the glucose levels in the blood. Sympathetic division stimulates alpha cells 
of the pancreas to release glucagon, which increases the glucose level in the blood. 
Parasympathetic division stimulates the release of insulin and pancreatic juice by the pancreas, 
to digest food and store glucose, which reduces the glucose level in the blood. The endocrines 
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system uses two hormones to regulate the digestive function of the pancreas. Secretin helps to 
maintain a neutral pH in the stomach. Cholecystokinin contributes to the digestion of large 
protein and lipid molecules that are difficult to break down [3]. 
 
Figure 1. The exocrine and the endocrine of pancreas. The pancreas has a head, a body and a tail. It delivers 
pancreatic juice to the duodenum through the pancreatic duct [4]. 
1.1.3 Common pancreatic problems 
Diabetes: Diabetes is a condition where the amount of sugar in the blood is too high, which is 
caused by the malfunction of the pancreas. The pancreas loses the ability to produce and 
release insulin, so the sugar level can’t be lowered in the blood. Diabetes patient will feel very 
thirsty, pass more urine than normal, lose weight and feel tired [5].  
Pancreatitis: The pancreas becomes inflamed and damaged by its own digestive chemicals. It 
can occur as acute painful attacks lasting a matter of days, or maybe a chronic condition that 
progresses over a period of years. Sometimes it will be life-threatening. Alcohol or gallstones 
can contribute to it, but the real cause of the most pancreatitis is unknown [6]. 
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1.2 Cancer 
Cancer is a disease caused by abnormal cell growth and it has the potential to spread to other 
parts of the body. It is one of the leading causes of death worldwide. For example, in 2014, 
cancer is responsible for 8.2 million deaths around the world [7]. The earliest written record 
in the history of cancer is from approximately 1600BC in Egyptian, which describes breast 
cancer [8]. However, till now, there is still no cure for most cancer. 
Actually, cancer is mainly a genetic disease, which is caused by changes in genes that control 
our cells functions, especially those related to cell growth and division. In general, they are 
three types of genes highly responsible for cancer, which are: proto-oncogenes, tumor 
suppressor genes and DNA repair genes. When proto-oncogenes are altered, they will become 
cancer-causing genes, which allow cells to grow and survive when they shouldn’t. When 
tumor suppressor genes are mutated, they will allow cells to divide without control. If DNA 
repair genes are changed, that will make cells become cancerous. In a word, some gene 
mutations cause cancer. 
They are many types of cancer, since it can start almost everywhere, such as leukemia, 
lymphoma, melanoma, carcinoma, brain cancer and so on. Many cancers form solid tumors, 
but some are not, for example, leukemia. For those that can form tumors, there are generally 
two types: malignant tumors and benign tumors. Benign tumors don’t invade or spread to 
nearby tissues, once removed, they usually don’t grow back. However, unlike benign tumor, 
malignant tumors can spread into or invade nearby tissues. By travelling through the blood or 
the lymph system, new tumors can be formed far from the original ones in benign tumor, 
which is life threatening. 
1.3 Pancreatic cancer  
Pancreatic cancer is the fourth leading cause of cancer-related death in both Europe and USA 
[9]. Despite many efforts have been put on it, the survive rate has not been improved in the 
past 30 years. Patients who diagnosed with pancreatic cancer will die within 6 months and the 
5 years survival rate is less than 5% [10]. This because it is often diagnosed at a late stage and 
it’s highly resistant to chemo and radiation therapy [11]. The most effective treatment for 
pancreatic cancer is surgery, however, only 20% of patients are suitable for surgery because 
when diagnosed it has already spread and 80% of patients after surgery suffer a relapse of the 
cancer [12]. For 2017, the American Cancer Society estimates that in the United States about 
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53,670 people will be diagnosed with pancreatic cancer and about 43,090 people will die of 
pancreatic cancer.  Hence, it is very urgent and important to study and research in the field of 
pancreatic cancer, hoping that it will improve the conditions of the patients and provide new 
insights to fight against it. 
1.3.1 Molecular biology of pancreatic cancer  
Currently, it’s still unknown what the exact causes of pancreatic cancer, but risk factors have 
been identified. Cigarette smoking, family history of pancreatic cancer, diabetes mellitus, 
heavy alcohol consumption (>60 mL ethanol/day) and history of pancreatitis are considered 
to be the most significant risk factors for pancreatic cancer [13, 14]. Scientists reported that 
25% of pancreatic cancer cases are related to smoking and pancreatic cancer developed 20 
years earlier in smokers than in nonsmokers [15, 16]. Researchers showed that inherited 
genetic variants contribute to at least 5%-10% of all pancreatic cancer cases [17-19]. The 
following genes with variants have been considered can increase the risk for pancreatic cancer 
in PDAC familial cases: BRCA1, BRCA2, PALB2, ATM, CDKN2A, APC, MLH1, PMS2, 
PRSS1 and STK11 [20]. Diabetes patients are also more likely to be diagnosed with 
pancreatic cancer [21].  
As mentioned before cancer is a gene related disease, so does pancreatic cancer. Scientists 
analyzed pancreatic tumor tissues and found that on average there are 63 genetic alterations 
relevant to tumor progression per sample [22]. Some gene mutations are present in almost all 
pancreatic samples. These genes include: KRAS, INK4A/ARF, SMAD4 and p53 [23-25]. 
KRAS is a GTPase that encoded by KRAS gene, it functions as a second messenger in growth 
factor receptor signaling pathways that stimulate the transition through the G1 phase of the 
cell division cycle. Approximately 90% of identified pancreatic cases have KRAS mutations 
[26]. When KRAS is mutated, it will impair the intrinsic GTPase activity resulting in a 
protein that is constitutively active in signal transduction, which will alter cell proliferation, 
survival and migration [27]. KRAS is considered as an oncogene in pancreatic cancer, and its 
mutation appears early during the process of pancreatic carcinoma [28]. Researchers have 
shown that KRAS is required for both the initiation and maintenance of pancreatic cancer in 
mice [29]. So KRAS could be the potential target for the therapeutic treatment of pancreatic 
cancer. 
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INK4A and ARF are two genes that are encoded in an overlapping region of the chromosome 
9. INK4A functions as an inhibitor of G1 cyclin-dependent kinase. The name of ARF implies 
that an alternate reading frame from INK4A encodes it. ARF family members encode small 
guanine nucleotide proteins and play a role in vesicular trafficking. These two genes are 
tumor suppressors and about 85% of pancreatic cancers are mutated in them [30]. Researches 
found that activated KRAS and INK4A/ARF deficiency cooperate to promote the 
development of pancreatic cancer [31]. ARF is found to be an activator of the p53 pathway, 
but it has p53-independent functions, such as inhibition of NF-κB activity, degradation of E2F 
and reducing the synthesis of ribosomal RNA [32]. Hence, when INK4A/ARF loss their 
function, many pathways will be influenced, cancer may begin to develop. 
SMAD4 is the number 4 protein of SMAD family, which functions as a signal transduction 
protein. This family plays a core role in the transforming growth factor-β (TGF-β) pathway, 
as shown in Figure 2. SMAD4 gene is found to be inactivated in about 55% of pancreatic 
cancers [33]. It is a tumor suppressor gene, its inactivation related to the development of 
pancreatic tumors. Normally, when TGF-β binds to their transmembrane receptors, after a 
series of phosphorylation, a SMAD4/SMAD complex transmit into the nucleus, binds to 
specific DNA sequence and activates gene transcription [34]. However, when SMAD4 is 
inactivated, many functions of TGF-β, such as growth suppression and apoptosis are no 
longer existed. Evidence showed that SMAD4 deficiency accelerates KRAS mediated 
pancreatic tumor development [35].  
p53 is a transcriptional activator, it plays an important role in cell cycle control and apoptosis. 
In a healthy cell, p53 protein level is low, however, when there is stress, such as DNA 
damage or hypoxia, it will be activated. p53 mainly has three functions: growth arrest, DNA 
repair and apoptosis. Over 50% of pancreatic tumors have p53 mutations [36, 37]. And in 
pancreatic cancer, p53 is often mutated in its DNA-binding domain, which will damage a lot 
of gene transcription, thus cells with abnormal DNAs remain growing. It’s a star molecule in 
cancer, over 50% of all human tumors have p53 mutations [38]. Unlike other tumor 
suppressors, research found that most of p53 mutations are missense mutations, but the reason 
for that remains unknown. 
Despite these most frequently mutated genes in pancreatic cancer, there are also other gene 
mutations found in PDAC, such as oncogenes: BRAF, AKT2, MYB and AIBI; tumor 
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suppressor genes: p21, p16/CDKN2A; genome maintenance genes: MLH, MSH2, BRCA2 
[27, 39], which we are not going to be discussed in details in this thesis. 
 
Figure 2. The transforming growth beta (TGF-β) signaling pathway. TGF-β binds to type II TGF-β receptor 
(TβRII), inducing the association of TβRII and TβRI, which activate TβRI. TβRI then phosphorylates Smad2 or 
Smad3.  Activated Smad2 or Smad3 associates with Smad4 and then translocate to the nucleus to influence the 
target gene expression [40]. 
Besides genetic abnormalities, epigenetic aberrations have also been found in PDAC. There 
are mainly three epigenetic modifications that affect gene expression, which are DNA 
methylation, histone modification and microRNA expression. Studies showed that more than 
90% of pancreatic cancers have aberrantly methylated PENK. Other genes that are found 
highly methylated in pancreatic cancer are: SPARC, CDKN2A/p16 and CDH1 [41]. Mucins, 
which play important roles in carcinogenesis, found undergo histone alterations in pancreatic 
cancer [42]. MicroRNAs are some non-coding RNA molecules, which negatively regulate the 
expression of target genes. In PDAC, several miRNAs have been shown over expressed, such 
as miR-155, miR-222, miR-221 and miR-21 [43].  
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The core signaling pathways that are highly related pancreatic cancer have also been studied. 
Besides the commonly mentioned Hedgehog and Notch pathway, the Wnt/Notch signaling 
pathway, small GTPase-dependent signaling pathway and integrin signaling pathway also 
involved in pancreatic cancer [22]. 
1.3.2 Pancreatic desmoplasia 
Solid tumors are organ-like structures, they are not only consist of tumor cells but also contain 
immune cells, fibroblasts, lymphocytes, macrophages, bone marrow-derived inflammatory 
cells, blood vessels and extracellular matrix (ECM), which form a cellular environment called 
tumor microenvironment [44]. During cancer, the tumor and its microenvironment constantly 
interact with each other to promote the process of cancer. Researchers have showed that 
tumor microenvironment maybe the leading player in the initiation of carcinomas. Such as 
mutations in stromal cells that specifically regulate paracrine growth factor expression have 
been found initiated epithelial cancer [45, 46]. Cancer cells’ ability to invade and metastasize 
has also been shown influenced by tumor microenvironment [47, 48]. In addition, studies 
found that cancer cells promoted the form of the tumor microenvironment by releasing 
various extracellular signals, such as cytokines, hormones, growth factors and so on [49, 50]. 
Another problem caused by tumor environment is hypoxia. Most solid tumors contain some 
regions of hypoxia. These regions are deprived of oxygen and are likely to have a decreased 
supply of nutrients such as glucose and essential amino acids. Tumor cells in these regions 
have to undergo oxidative metabolism, which will lead to low interstitial pH or acidosis inside 
the tumor. The lower pH in the tumor microenvironment will influence the cytotoxicity of 
anticancer drugs [51]. Tumor hypoxia also activates angiogenesis and cell survival related 
genes, which may lead to a more aggressive tumor type [52, 53]. Such as, hypoxia stimulates 
the transcription of vascular endothelial growth factor (VEGF), transforming growth factor-β 
(TNF-β), platelet-derived growth factor-β (PDGF-β) and insulin-like growth factor, which 
promotes tumor growth [54]. In a word, tumor hypoxia in the microenvironment is strongly 
associated with tumor propagation and influences cancer treatment. 
Scientists mainly focused on cancer cells to fight against tumors and they achieved significant 
advances in colorectal cancer, lung cancer and melanoma [55]. Unfortunately, the same 
method wasn’t successful in pancreatic cancer. A peculiar hallmark of pancreatic cancer is the 
presence of high percent of reactive stroma that can cumulate up to 90% of the tumor mass, as 
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showed in Figure 3 [56, 57]. And in recent years, an accumulating body of evidence suggests 
that the highly reactive stroma of pancreatic microenvironment is one of the prime reasons of 
the tumor aggressiveness and resistance to therapy. Researcher found that this massive stroma 
contributes to an increase interstitial fluid pressure inside of the tumor [58] and causes 
hypoxia in the tumor [59],  which makes it more difficult to find a good therapy for PDAC. 
Therefore, targeting stroma could be a new way to fight against pancreatic cancer.  
 
Figure  3. Colocalization of collagen and αSMA staining in pancreatic cancer [60]. Stroma exists positive stain 
for collagen I and αSMA. 
The dense desmoplasia of pancreatic cancer is also formed by many kinds of cells, such as 
endothelial cells, leukocyte, macrophages, inflammatory cells, nerve fibers and marrow-
derived stem cells. Among them, there is one type of cell we just can’t ignore, pancreatic 
stellate cells (PSCs). PSCs are generally quiescent during normal physiology, but when in the 
event of inflammation or cancer these cells are activated, differentiate to myofibroblast-like 
cells, proliferate, migrate and start secreting extracellular matrix (ECM) proteins, which are 
the main contributors to pancreatic fibrosis during the course of pancreatitis and pancreatic 
cancer. The details of pancreatic stellate cells will be discussed below. 
1.3.2.1 Pancreatic stellate cells 
Pancreatic stellate cells were first observed in 1982 by using autofluorescence and electron 
microscopy [61]. Then Apte [62] and Bachem [63] isolated stellate cells from rat and human 
pancreas, the study of PSCs began to develop. Early studies of PSCs based on the knowledge 
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and experience gained from hepatic stellate cell, which were first described in 1876 by Karl 
von Kupffer [64]. Stellate cells have a star like shape and they are also present in other tissues, 
including the kidney and lung [65, 66]. 
PSCs are specific stroma cells of pancreatic cancer, they generally have two states: 
quiescence and activation. In health pancreas, stellate cells are quiescent, they are located at 
the basolateral aspect of acinar cells and constitute approximately 4% to 7% of pancreatic 
cells [67]. They are round shape and fat storing cells, can be identified by the presence of 
abundant vitamin A and the expression of cytoskeletal proteins such as glial acidic fibrillary 
protein (GAFP) and desmin [62, 63, 68, 69]. By secreting matrix degrading enzymes and 
inhibitors of these enzymes, PSCs play a crucial role in maintaining the regular ECM turnover 
during health [70]. A study in 2010 also demonstrated that PSCs might play a role in 
regulating enzyme secretion from acinar cells [71].  
During inflammatory or cancer, PSCs undergo various changes. They loss the vitamin A 
droplets, become myofibroblast-like cells, proliferate, migrate and produce extracellular 
matrix proteins such as collagen I, fibronectin, laminin, which make great contributions to the 
stoma formation in pancreatic cancer [72-76]. In addition, activated PSCs secrete cytokines, 
chemokines, which work as feedback loops making PSCs more activated [77-79]. What’s 
more, other neighboring cells in the microenvironment such as acini, tumor, immune cells and 
platelets, work in a paracrine manner, stimulating the activation of PSCs, which promotes 
desmoplasia further [80]. A lot of factors have been shown involved in the activation of PSCs, 
such as transforming growth factor (TGF)-β1, tumor necrosis factor (TNF) α, platelet-derived 
growth factor (PDGF), vascular endothelial growth (VEGF) factors, interleukin (IL)-1, IL-6, 
IL8, IL-10 [63, 76]. The most potent activators of PSCs are believed to be TGF-β1 and PDGF. 
TGF-β1 is a fibrogenic mediator that stimulates the ECM synthesis of activated PSCs [81, 82] 
and IL-1 and IL-6 were found to affect the activation of PSCs through the production of TGF-
β1 [83]. PDGF induces the proliferation and migration of PSCs [84, 85]. Besides factors 
mentioned above, there are other potential sources related to the activation of PSCs, such as 
pressure, oxidative stress, ethanol and its metabolites, as well as the composition changes in 
the ECM [82, 86, 87]. Figure 4 showed the mechanisms of pancreatic stellate cells activation. 
In recent years, several signaling pathways and molecules that are important in the process of 
PSCs activation have been identified, which are peroxisome proliferator activated receptor 
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gamma (PPARᵧ), protein kinase C (PKC), the JAK-STAT pathway, the PI3K-AKT pathway, 
Rho kinases and transcription factor nuclear factor-kappa B (NF-κB) and so on [88].  
 
Figure 4. Mechanisms of pancreatic stellate cells activation. Growth factors and pro-inflammatory cytokines 
released by PSCs and its neighboring cells all induce PSCs activation [89]. 
PPARᵧ, also known as the glitazone receptor, is mainly present in adipose tissue. It can 
regulate fatty acid storage and glucose metabolism [89-91]. Researchers showed that 
overexpression of PPARᵧ blocks the activation of pancreatic stellate cells and down regulation 
of PPARᵧ is associated with PSCs activation [92]. Protein kinase C is a family of protein 
kinase enzymes. They are known for their long-term activation: they remain activated after 
the original activation signal is gone. Angiotensin II has been found to be able to promote the 
proliferation of activated PSCs through a protein kinase C pathway [93]. The JAK-STAT 
signaling pathway is a pathway that can transmit information from extracellular chemical 
signals to the nucleus. The activation of JAK-STAT is related to the activation of PSCs. 
PDGF was found stimulated the proliferation of PSCs via JAK-STAT pathway [94]. The 
PI3K-AKT pathway is also involved in the regulation of PSCs. PDGF promotes the migration 
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of PSCs through PI3K-AKT pathway [95]. Rho kinases play a role in regulating the shape 
and movement of cells. Treating PSCs with Rho kinase inhibitors blocks the activation of 
freshly isolated PSCs in culture [81]. NF-κB is a protein complex that controls transcription 
of DNA, cytokine production and cell survival. Researchers found that activated PSCs 
express a variety of NF-κB responsive genes [96]. There are other pathway proteins relate to 
the activation of PSCs, such as activator protein-1 (AP-1), Smad proteins, Hypoxia-inducible 
factors (HIF-1), Reactive oxygen species and Indian hedgehog (IHH), we are not going to 
explain them in details here [97-101]. 
After activation, PSCs have two fates, if the injury is not that severe, PSCs will lose their 
active phenotype and become quiescent again. If the injury is severe and continuous, PSCs 
will remain active and pancreatic fibrosis will develop. Irreversible activation of PSCs will 
cause the composition changes of the extra cellular matrix, which means that collagen I will 
deposit and fibrosis begins. The origin of PSCs has also been studied. Researcher showed that 
bone marrow-derived progenitor cells contribute around 5% to the PSCs population [102]. 
Some studies proved that PSCs are derived from pancreas precursor [103]. The contribution 
of endothelial cells to the myofibroblast cell population in pancreatic cancer has also been 
reported [104]. 
1.3.2.2 Tumor stroma interactions 
Considering the large amount of stroma in pancreatic adenocarcinoma, the role it plays in the 
process of cancer just can’t be ignored. Researchers found that the interactions between PSCs 
and pancreatic cancer cells can influence the progression of pancreatic cancer. On the one 
hand, pancreatic cancer cells not only secrete different kinds of growth factors such as 
transforming growth factor-β1 (TGF-β1), platelet-derived growth factor (PDGF), Vascular 
endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), which can 
activate PSCs and thus stimulate proliferation, migration and matrix synthesis of cultured 
PSCs [63, 74, 76, 80, 105], but also they can produce MMPs, which digest stroma and release 
stored growth factors in the stroma, aiding in the desmoplastic reaction in PDAC [106]. 
Besides these factors mentioned above, two secretory proteins: cyclo-oxygenase-2 and trefoil 
factor 1, which is up regulated by pancreatic cancer cells, have also been reported can 
promote the proliferation of PSCs [60, 107]. 
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On the other hand, scientists noticed that pancreatic stellate cells are important in promoting 
pancreatic cancer cell proliferation, invasion and metastasis [80]. An in vitro study showed 
that pancreatic stellate cells promote proliferation and invasiveness of human pancreatic 
cancer cells via galectin-3 [108].  A three dimension in vitro research proved that pancreatic 
stellate cells increase the invasion and epithelial-mesenchymal transition of pancreatic cancer 
cells [109]. In a subcutaneous mouse model of pancreatic cancer, it has been shown that 
animals injected with both PSCs and pancreatic cancer cells grew much bigger tumor than 
animals injected with cancer cells alone [110]. In another orthotopic model of pancreatic 
cancer, injection of pancreatic cancer cells and PSCs together into the pancreas of mice, 
histology experiments verified that activated PSCs are related to fibrosis and co-injection 
experiment mouse demonstrated larger tumors and more local and distant metastases than 
mouse only injected with tumor cells alone [111]. In pancreatic cancer patients, researchers 
found that extensive fibroblastic cell proliferation correlates with poor disease outcome [112].  
PSCs also have been found to play a role in regulating epithelial-mesenchymal transition 
(EMT) and stemness of cancer cells. EMT is a well-known hallmark of highly invasive cancer 
cells. When cells go epithelial mesenchymal transition, they will lose their cell polarity and 
cell-cell connections, and begin to migrate and invade. Researchers showed that PSCs 
promote EMT in pancreatic cancer cells. Cancer cells grow with PSCs gaining a fibroblast-
like appearance and begin express mesenchymal markers, such as vimentin and zeb [113]. 
Stemness is the ability to self-renew and differentiates. Cancer stem cells have the ability to 
move to distant sites and retain their stemness properties and thus grow new tumors at these 
sites. Researchers found that PSCs enhance stem cell-like phenotypes in pancreatic cancer 
cells. Hamada [114] showed that when co-cultured pancreatic cancer cells with PSCs, the 
spheroid-forming ability of pancreatic cancer cells was increased and some stem cell related 
genes were expressed in cancer cells. Al-Assar [115] demonstrated that PSCs enhanced 
cancer stem cell phenotype and radio resistance of pancreatic cancer cells. 
1.3.2.3 Macrophages 
Macrophages are a type of white blood cell that engulfs and digests unwanted particles, such 
as cell debris, foreign substances, microbes, and so on, which is an important part of our 
immune system. Generally, macrophages can divide into two types: (1) classically activated 
macrophages or called M1 macrophages. It encourages inflammation and during acute 
infectious diseases it provides host protection against bacteria and viruses [116, 117]; (2) 
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alternatively activated macrophages or called M2 macrophages. It plays a key role in 
dampening inflammation, promotes wounding healing, fibrosis and tumorigenesis [118, 119]. 
Both M1 and M2 macrophages are existed in the pancreatic tumor microenvironment. These 
macrophages have been postulated as being involved in the process of cancer [120, 121]. Liu 
demonstrated that the migration and proliferation of pancreatic cancer cells were increased 
when co-culture of tumor associated macrophages with pancreatic cancer cells [122]. 
Macrophages also interact with pancreatic stellate cells. Shi showed that quiescent PSCs were 
activated when co-culture with macrophage cell lines and PSCs in turn increased the cytokine 
production of macrophages [123].  
1.4 Pancreatic cancer models 
In order to simulate the in vivo environment of pancreatic cancer, models have been built for 
a better understanding of the biology of pancreatic cancer. These models include: three-
dimensional in vitro models and in vivo mouse models. 
Three dimension (3D) models often consist of a matrix, which is composed of extracellular 
proteins such as collagen and basement membrane proteins, with the cells or tissue cultured 
on top or within the matrix [124]. It allows the study of cell-cell and cell-ECM interactions, in 
addition to the influence of the microenvironment on cells. At present time, the most widely 
used three dimension system is multicellular tumor spheroids [125]. Spheroids are aggregates 
of cells grown in suspension or embedded in a 3D matrix using 3D culture methods [126]. 
They can be used to study tumor growth and proliferation, invasion, matrix remodeling, 
immune interactions and drug screening [127]. Compared to 2D models, 3D models have 
many advantages. They make it possible to capture and quantify invasion, which is not 
possible in 2D culture. Also, in cancer, they provide a very good method to study how tumor 
microenvironment interacts with cancer cells. Besides, they resemble more closely the in vivo 
situation [124]. However, they also have their limitation, the matrix composition and stiffness 
will alter cellular response and the thickness of the matrix will affect the nutritional status of 
cells [128]. 
For in vivo mouse models, there are mainly three kinds: xenograft mouse models, carcinogen 
induced mouse models and genetically engineered mouse models, showed in Figure 5. 
Xenograft mouse model of pancreatic cancer is created by transplanting human pancreatic 
cancer cell lines under the skin of immune compromised nude mice. They can be used to 
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study cancer cell/host cell interactions and the efficacy of new anticancer drugs [129]. For 
these models, it is easy to measure tumor dimensions after resection. However, it’s impossible 
to study metastasis by using these models and they ignore the contribution of the host immune 
system in the tumor progress [130]. Orthotopic mouse models are a little bit more 
complicated. They generated by injecting cancer cell into the mouse pancreas. They can help 
to study the tumor in its native position but they are expensive and technically difficult. 
Carcinogen induced models are generated by treating mice with certain chemicals that will 
lead to pancreatic cancer. Such as intraperitoneal injection of N-nitrosobis(2-oxopropyl)amine 
in hamsters [131]. Since about 70% of human tumors are induced by carcinogens, chemically 
induced models are of particular value. These models can be used to assess risk factors and 
find possible preventive and therapeutic methods for cancer [132]. However, these 
carcinogens also affect other organs, so the usage is limited. As mentioned above, pancreatic 
cancer is a gene related disease, so using genetically engineered mouse models to mimic 
relevant genetic mutations in pancreatic cancer is an invaluable tool to study cancer. And 
compared to xenograft tumors, genetically engineered mouse models are considered as an 
even closer approximation of human disease conditions [133]. 
 
Figure 5. Mouse models of pancreatic cancer: genetically engineered models and xenograft models are currently 
considered to best recapitulate the human pancreatic adenocarcinoma [134]. 
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1.5 EP300 
EP300 is short for E1A-associated protein p300. It is a large size protein and has a molecular 
weight of about 300 kDa. This protein is commonly expressed in human tissues and highly 
evolutionary conserved and present in many organisms including flies, worms and plants. It is 
a nuclear protein and mainly has three different functions: (1) Acetylation of histones tails. 
EP300 can acetylate promoter nucleosomal histones resulting in chromatin remodeling and 
relaxation, thus increase accessibility of the DNA to regulators. (2) Acetylation of other target 
proteins. EP300 can acetylate transcriptional factors such as E2F, HMGI and HNF4, 
modulating their activity and causing either positive or negative effect on transcription. (3) 
RNA Polymerase II stabilization. EP300 can work as a bridge to link the DNA-bound 
transcription factors to the basal transcription machinery [135]. 
Besides the functions mentioned above, EP300 also involves in a lot of biological processes, 
such as proliferation, cell cycle regulation, apoptosis and differentiation [136-138]. Evidences 
showed that EP300 activity is required for G1/S transition [139, 140]. Down regulation of 
EP300 inhibits apoptosis, which is possible by damaging the p53-mediated response to DNA 
damage [141]. Furthermore, EP300 is often found mutated or in a truncated form in various 
human tumors, such as colorectal cancer, gastric cancer, ovarian cancer, breast cancer and 
pancreatic cancer [142-144]. Research showed that lower expression of EP300 in colon 
carcinoma cells induces these cells to go epithelial mesenchymal transition [145]. And EP300 
proved to be a tumor suppressor gene in metaplastic breast cancer [146]. EP300 has also been 
implicated in embryonic development. It is showed that EP300 and CBP knockouts are early 
embryonic lethal and these two genes are essential for mammalian cell proliferation and 
development [147]. 
The crystal structure of human EP300 has been well studied. It mainly has three catalytic 
cores: bromodomain, CH2 region and HAT domain.  The CH2 region includes a PHD domain 
and a RING domain, showed in Figure 6 [148]. Mutations that inactivate the HAT domain are 
found in various cancers [149], mutations in the PHD domain are found in Rubinstein-Taybi 
syndrome [150]. Cancer-related mutations in the RING domain has been found lead to an 
increase in EP300 histone acetyltransferase activity [148]. Studying the core structure of 
EP300 and understanding the difference between different disease-related EP300 mutations 
may have important implications for pharmacological targeting. 
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Figure 6. Domain architecture of EP300. The bromodomain, RING and PHD domains are shown in yellow, 
green and red, respectively. The N and C subdomains of HAT domain are shown in blue and gray, respectively 
[148]. The author of this thesis modified the picture. 
1.6 Aim of the study 
As mentioned above, EP300 is an important transcription coactivator and participates in 
regulating cell proliferation, differentiation and apoptosis. Moreover, it has been found 
mutated in pancreatic cancer. Additionally, in PDAC, PSCs change from quiescent cells to 
active cells, they differentiate to myofibroblast-like cells, begin to proliferate and migrate. 
Therefore, we hypothesized that targeting EP300 may affect the activation of PSCs and 
influence the communications between PSCs and pancreatic cancer cells. Hence, we are going 
to explore the gene functions of EP300 in PSCs in the current study. 
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2 Materials and Methods 
2.1 Materials 
Table 1 Cell lines 
Cell lines Resources 
 
Immortalized PSCs 
 
 
A gift from Ralf Jesnowski [69], Mannheim Univerisity 
Hospital 
Bxpc-3 Authentificated by DKFZ, Heidelberg, Germany 
Panc-1 Authentificated by DKFZ, Heidelberg, Germany 
 
Table 2 Antibodies 
Product Company Catalogue Number 
AKT antibody Cell signaling 9272 
Anti-mouse IgG(H+L) Peroxidase Biozol VEC-PI-2000 
Anti-rabbit IgG(H+L) Peroxidase Biozol VEC-PI-1000 
Col-I antibody Abcam Ab34710 
EP300 antibody Abcam Ab3164 
ERK1/2 antibody Cell Signaling 9102 
Fibronectin antibody Sigma Aldrich F3648 
GAPDH Sigma-Aldrich G9295 
pAKT antibody Abcam Ab81283 
Phopho-ERK 1/2 antibody Cell Signaling 4307 
pSTAT3 antibody Abcam Ab76315 
STAT3 antibody Cell signaling 8768 
α smooth muscle actin antibody Acris 14395-1-AP 
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Table 3 Kits 
Product Company Catalogue Number 
BCA Protein Assay Kit Thermo Scientific 23225 
Fast SYBR
®
 Green Master Mix Thermo Scientific 4385612 
Go Taq Green Master Mix Promega M7122 
Immobilon western chemiluminescent HRP 
substrate  
Millipore WBKLS0500 
RevertAid First strand cDNA synthesis kit Life technology K1622 
QIAquick
® 
Gel extraction
 
kit Qiagen 28704 
DNeasy Blood & Tissue Kit Qiagen 69504 
 
Table 4 Reagents  
Product Company Catalogue 
Number 
1,2-Bis (dimethylamino) ethane(TEMED) Roth 2367 
12-Maltoside Sigma-Aldrich D4641 
Accutase Sigma-Aldrich A6964 
Acrylamid-stammlösung 30% Rotiphor 12623 
Agarose Sigma-Aldrich A9539 
Albumin from bovine serum Sigma-Aldrich A2153 
Ammoniumpersulfate (APS) Sigma-Aldrich A3678 
ASB-14 Sigma-Aldrich A1346 
Benzonase nuclease Merck 70746-4 
Bicine Sigma-Aldrich B3876 
C646>98%(HPLC), 5mg The Geyer SML0002 
Chloroform Sigma-Aldrich 288306 
DMEM Life Technologies 41965062 
DMSO Genaxxon Bioscience M6323.0100 
DNA Gel loading dye(6×) Thermo Sicentific R0611 
DPBS Life Technologies 14040174 
Ethanol, absolute Sigma-Aldrich 24102 
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Ethylenediaminetetraacetic acid disodium salt 
dihydrate (EDTA.2Na) 
Sigma-Aldrich E5134 
FBS Life Technologies 10500064 
Gemcitabine Biomol Cay11690-10 
Generuler Low range DNA Ladder, ready to 
use 
Life Technology SM1193 
Glycerol Sigma-Aldrich G5516 
Glycine for electrophoresis Sigma-Aldrich G8898 
Glycogen, RNA grade Fisher Scientific R0511 
Halt
TM
 Protease and Phosphatase inhibitor Thermo Sceintific 78443 
Hydrochloric acid (HCl), 37% VWR international 85848.290 
IMDM (with phenol red) Life Technologies 21980065 
IMDM (without phenol red) Life Technologies 21056023 
Isopropanol Sigma-Aldrich W292907 
Laemmli Sample Buffer 4× Bio-Rad Laboratories 161-0747 
LightCycler 480 Multiwell Plate 384,white Roche 04729749001 
Methanol Sigma-Aldrich 322415 
Millex-GP, 0.22µm filter EMD Millipore SLGP033RS 
Mission predesigned siRNA Sigma-Aldrich PDSIRNA2D 
Na-cholate Sigma-Aldrich C6445 
Nonfat dry milk Bio-Rad Laboratories 170-6404 
NP-40 Sigma 74385 
Nuclease-free water Life Technologies AM9939 
PBS Life Technologies 10010056 
PepGREEN DNA/RNA dye VWR 37-5010 
Pen/Strep Life Technologies 15140122 
PMSF Cell Signaling  8553 
Ponceau S solution Serva 33427.01 
Positive control siRNA Sigma-Aldrich PDsiRNAPC2D 
Prosie Quadcolor protein marker4.6-300kda Biozym 830537 
Resazurin  Fisher Scientific 10684882 
Restore Plus western blot stripping buffer Life Technologies 46430 
RNase ZAP
TM
 Sigma R2020-250ml 
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RNaseOUT
TM
 Ribonuclease inhibitor Invitrogen 10777-019 
siRNA transfection reagent, X-treme Roche 04476093001 
Sodium Acetate Solutaion 3M Life Technologies R1181 
Sodium Chloride (NaCl) Sigma-Aldrich S9888 
Sodium dodecyl sulfate(SDS) Sigma-Aldrich 71725 
Sodium hydroxide Fisher Scientific 11958484 
Spectra Multicolor Broad Range Protein 
Ladder 
Life Technologies 26634 
T7 Endonuclease 1 NEB M0302S 
TMB Liquid substrate system for ELISA Sigma-Aldrich T0440 
Triton X-100 Sigma-Aldrich T8787 
Trizma
® 
Base Sigma-Aldrich T1503 
Trizma
® 
HCL Sigma-Aldrich T3253 
Trizol Reagent Invitrogen 15596-0108 
Trypsin (0.05%) Life Technologies 25300062 
Tween
® 
 20 Sigma-Aldrich P2287 
U0126 Abcam Ab120241 
X-treme GENE HP DNA transfection reagent Roche 06366244001 
 
Table 5 Buffers and Solutions 
Name         Composition 
1×TBST 100ml  10×TBS,  1ml Tween 20, dilute it in 900 H2O  
10%APS 1gAPS, 10ml H2O 
10%SDS 10g SDS, 100ml H2O 
10× Laemmli running buffer 30g Tris base, 10g SDS, 144g Glycin ,  1L H2O 
10×TBS 31.52g Tris HCl, 80g NaCl, add 900ml H2O, adjust pH to 7.6, 
then fill the bottle to 1L  
 
4×Loading buffer for western 
(10ml) 
2.0ml 1M Tris-HCl, 4.0ml 100% glycerol,  
1.0ml 0.5M EDTA, 8mg bromophenol blue  
0.8g SDS, 0.4ml 14.7 M β-mercaptoethanol 
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5% Milk 10g fat skim milk powder and solve it in 200ml TBST 
Anode I buffer 36.4g Tris base, 200ml Methanol, fill it up to 1L with H2O 
Anode II buffer 3g Tris base, 200ml Methanol, fill it up to 1L with H2O 
Cathode buffer 3g Tris base, 5.2g 6-aminocaproic acid, 200ml Methanol, fill 
it up to 1L with H2O 
Lysis buffer (10ml) NP-40(20%) 500µl, Na-cholate (10%) 1000µl,  
ASB-14 (5%) 1000µl, 12-Maltoside(2.5%) 1000µl, 
Glycerol(99%) 2000µl, Bicine (0.5M, pH 8.5) 1000µl 
NaCl(1.50M) 1000µl, EDTA.2Na(0.02M) 1000µl 
PMSF(200mM) 50µl, Pro&Phosph inbihitor 100µl 
Benzonase 4µl, dH2O 1346µl 
 
PBST 1×(1L) 8g NaCl, 0.2g KCl, 1.44g NaHPO4, 0.24g KH2PO4 
1ml Tween 20, adjust pH to 7.4 
 
Sammel Buffer 47.28g TrisHCl in 200ml dH2O, adjust pH to 6.6 with NaOH 
TBE Buffer 10×(1 L) 108g Tris, 55g Boric acid, 40 ml 0.5M Na2EDTA, pH 8 
Trenn Buffer 36.33g Tris.Base in 200ml dH2O, adjust pH to 8.8 with HCL 
Western wet transfer buffer 3g Tris Base, 14.4g Glycine, 1gSDS, 800ml H2O, 200ml 
methanol 
 
 
Table 6 Materials 
Product Company Catalogue Number 
8 strip PCR tubes (0.2ml) Life Technologies AM12230 
Adhesive PCR seal Biozyme 600208 
Amicon
® 
Ultra-0.5ml Centrifugal Filters 
Ultracel
®
 -3K 
Merck Millipore UFC500396 
Cell culture flasks 175cm DKFZ Lager 12649 
Cell culture flasks 25cm DKFZ Lager 13640 
Cell culture flasks 75cm DKFZ Lager 12667 
Cell culture plates-6 well DKFZ Lager 657160 
Cell culture plates-96 well DKFZ Lager 655180 
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Cell Scraper, 39cm Neolab 100128121 
Cell Scraper, small 24cm Neolab 100128120 
Cover slips, square 0.22×0.22 mm Carlroth H87 
Cryovials, 1ml Greiner 123263 
Cryovials, 2ml Greiner 121261 
Eppendorf safe lock micro centrifuge tubes 
(0.5ml, 1.5ml and 2ml) 
Eppendorf 0030121594/ 
0030121597/ 
0030121570 
Filter tips 1000µl Biozym 701281 
Filter tips 20 µl Biozym 701221 
Filter tips 200 µl Biozym 701261 
Fisherbrand
TM 
Graduated Cylinders  
100,250ml, 1000ml 
Fisher scientific S63458 
S63459 
S63461 
Fisherbrand
TM
 Reusable Galss Media Bottles 
with Cap, 100ml, 250ml, 1000ml 
Fisher scientific FB800100 
FB800250 
FB8001000 
Flacon tube 15ml DKFZ Lager 14258 
Flacon tube 50ml  DKFZ Lager 12633 
GE Healthcare 3mm CHR blotting paper sheets 
46×57 cm 
GE Healthcare 3030917 
Gloves, Latex medical examination BM11228-PF-AV Blossom 
Gloves, Nitril Freeform SE FFS-700 Microflex 
HTS Transwell-96 system, 8µm Sigma-Aldrich CLS3374 
Light Cycler
®
 480 Multiwell plate 384, white Roche 04729749001 
Millex GS Filter, steril, 0.22μm Millipore SLGS033SS 
Mycoplasma ExS Spray Promo Cell PK-CC91-5051 
Nitrocellulose membrane 0.45µm GE Healthcare GE10600007 
Pasteur pipettes  230mm DKFZ Lager 12908 
PVDF membrane 0.45µm Merck Milipore IPFL10100 
Reservors,25ml Fisher Scientific 11475748 
Serological Pipettes 10ml DKFZ Lager 14301 
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Serological Pipettes 25ml DKFZ Lager 14302 
Serological Pipettes 5ml DKFZ Lager 14300 
 
Table 7 Equipments 
Name Manufacturer 
CO2 Water Jacketed incubator Thermo Life Science 
Electronic Balances, Kern 434,440-45 Kern & Sohn GmbH 
Fluostar Galaxy plate reader MTX Lab System 
Gilson Pipetman P1000 single channel pipette Gilson 
Gilson Pipetman P2 single channel pipette Gilson 
Gilson Pipetman P20 single channel pipette Gilson 
Gilson Pipetman P200 single channel pipette Gilson 
Ice maker Scotsman 
LAS-4000 mini Fujifilm Corporation 
Light Cycler system Roche 
Microwave oven Bosch 
Mini-PROTEAN Tetra Vertical Electrophoresis cell 
for Mini precast gels  
Biorad 
Nanodrop Spectrophotometer N1000 Thermo Scientific, USA 
PCR Thermocycler PTC200 MJ research BioRad, USA 
PH-Meter MP230 Mettler Toledo Mettler Toledo, Germany 
Power scanner Tecan 
Spectrafuge 3-1810 Centrifuge NeoLab 
Sterilgrad Hood Class II  Type A/B s The Baker Company 
TE 70 Semi-dry transfer unit   Amersham Bioscience 
TKA MilliQ water supply Millipore 
Vi cell XR cell viability analyzer, cell counter Beckman Coulter 
Vortex Mixer Neolad 
Water Bath Grant Instruments 
WILOVERT 30, Microscope Helmut Hund GmbH 
Heating Block Grant Instrument 
Microcomputer electrophoresis power supply Renner GmbH 
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Orbital Shaker Fröbel Instruments  
Mr. Frosty
TM
 Freezing Containers Thermo Fisher scientific 
 
2.2 Method 
2.2.1 Cell culture 
Immortalized human pancreatic stellate cells were a gift from Ralf Jesnowski[69]. Bxpc-3 and 
Panc-1 used in this article were authentificated by DKFZ internal service. All cell lines were 
cultured on 175 cm
2
 flasks in IMDM medium containing 10% fatal bovine serum, 50 
units/mL penicillin and 50µg/mL streptomycin at 37 °C with 5% CO2. Cells were separated 
every two days at a ratio of 1:5 and tested for mycoplasma contamination every month.  
For sub-culturing of these cells, when cells reached 80%-90% confluence, removed the old 
medium and washed the flask twice with PBS, then added 1ml of 0.05% trypsin per flask. 
Incubating them at 37 °C for 5-10min, once the cells were detached, medium containing 10% 
FBS was used to inactivate trypsin. Then cells were separated at the ratio mentioned before. 
For storage of cells, when cells reached 80-90% confluence, cells were detached as mentioned 
above. The cell suspension was centrifuged at 1500 rpm for 5 minutes and cell pellet was 
collected. The pellets were subsequently re-suspended in a cryoprotectant containing 60% 
FBS, 30% complete medium and 10% DMSO. One ml of cell suspension (around 1×10
6 
cells) 
was added to each cryovial. The vials were placed in a Mr. Frosty and stored at -80 °C for 1-2 
days, prior to being transferred to liquid nitrogen tank for long term storage. When recovering 
cells from liquid nitrogen tank, cells were thawed in a 37 °C water bath as quickly as possible. 
Then cell suspensions were transferred to a 15ml falcon tube containing pre-warmed complete 
medium, centrifuged and the supernatant was removed. Complete medium was used to 
resuspend the cells and cells were transferred into a culture flask for recovering. 
For counting of cells, cells were detached and well mixed. Then 500μl of cell suspension was 
put into the 4ml sample cup and counted by the Vi Cell counter. 
2.2.2 siRNA transfection 
PSCs were seeding on a 6-well plate 24 hours before transfection (1×10
5
/well), making sure 
that the cell confluence would reach 50%-60% at the time of transfection. Cells were treated 
with a mixture of 100nM EP300 siRNA (SASI_Hs01_00052818, sigma aldrich) and 20 µL X-
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tremeGENE siRNA transfection reagent (Roche Diagnostics) in a volume of 2 mL according 
to the manufacturer’s protocol. Scramble siRNA control was purchased from Santa Cruz. 
Seven hours after transfection, medium was changed to full growth medium. Cells were 
harvested 24 hours post transfection for real time quantitative PCR and 48 hours post 
transfection for western blot. For supernatant collection, cells were grown for 48 hours after 
transfection, serum free for 48 hours and then the media were collected. 
2.2.3 CRISPR/Cas9 gRNA transfection 
A commercial CRISPR plasmid pGS-gRNA-Cas9-Puro with gRNA sequence: 
TTTGCCGGGGTACAATAGG specifically targeting EP300 was bought from the company 
GenScript. The same plasmid with scramble gRNA sequence was served as control. Cells 
were seeded at 6-well plate 24 hours before transfection, making sure that they would reach 
80%-90% confluence at the time of transfection. X-tremeGene HP DNA transfection reagent 
were used according to the manufacturer’s instruction. Briefly 2µg plasmid and 8µL 
transfection reagent in a total volume of 2 mL were added in each well. 72 hours post 
transfection, cells were selected with 1µg/mL puromycin for approximately 14 days. Every 3 
days, fresh medium with puromycin was added. Surviving cells were pooled. T7 
endonuclease I assay (T7E1) was used to detect Cas9 induced mutations, western blot was 
used to check the protein expression. For supernatant collection, cells were seeding in a 
75cm
2
 flask for 24 hours, so they could reach 80-90% confluence, then serum free for 48 
hours and the media were collected. 
2.2.4 T7E1 assay 
Genomic DNA was extract from the stable knockdown cell lines by using a DNA extraction 
kit. A fragment of approximately 900bp was amplified from genomic DNA with the primer 
mentioned below. The PCR products were then purified on a 1.5% agarose gel and extracted 
by using a gel extraction kit. After that, 400ng purified DNA was denatured at 95 °C for 5 
minutes and slowly reannealed. Last, 1µL (10U) T7 endo I (NEB) enzyme was added and 
incubated at 37°C for 15min. The reaction was stopped by adding EDTA, and the digestion 
product was immediately run on a 1.5% agarose gel.  
2.2.5 C646 treatment 
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Normal PSCs were grown in a T75 flask (2.5×10
5
/flask), 24 hours later when the confluence 
of the cell would reach 80%-90%, serum free overnight.  Then cells were treated with 20µM 
C646 in serum free medium for 24 hours or 48 hours. Serum free medium was used since 
C646 was inhibited by serum. No longer treating time was done, because when cells were 
treating with C646 in serum free medium for 72h, they lose the viability. Cells treated with 
20μM DMSO were served as control, since C646 was dissolved in DMSO. 
2.2.6 Quantitative real time PCR (qRT-PCR) 
24 hours after siRNA transfection, the knockdown efficiency and gene expression of αSMA, 
FN and Col-I by PSCs were quantified with RT-PCR. Total RNA was extracted using Trizol 
reagent (Invitrogen). Briefly, 1ml of Trizol reagent was added to each well of the 6-well plate 
to lysis cells. Subsequently, RNA was separated with chloroform and precipitated out of the 
aqueous fraction with isopropanol and glycogen. 70% ethanol was used to wash the pellet 
twice. Then the pellet was dried and resuspended in water. RNA concentration was measured 
with Nano drop and 500 ng of RNA was used for the reverse transcription. cDNA synthesis 
was performed with a kit and following the instructor’s protocol. Quantitative real time PCR 
was performed using Light Cycler system (Roche) and Fast Sybr green (Life technology). All 
things were done according to the manufacturer’s protocol. HPRT1 was served as the control 
gene. The primer, reaction system and program used for real time PCR were as follows: 
Table 8 Primer 
Gene   Primer 
 
EP300 
 
 
Forward primer: 5’-GCAGTGTGCCAAACCAGATG-3’ 
Reverse primer: 5’-GGGTTTGCCGGGGTACAATA-3’    (105bp) 
 
αSMA Forward primer:5’- GAGGGAAGGTCCTAACAGCC-3’ 
Reverse primer:5’- TAGTCCCGGGGATAGGCAAA-3’ 
 
FN Forward primer:5’- GTCGGAGAAACGTGGGAGAA-3’ 
Reverse primer:5- GAAGTGCAAGTGATGCGTCC-3’ 
 
Col-I Forward primer: 5’-GCTCTTGCAACATCTCCCCT-3’ 
Reverse primer:  5’-CCTTCCTGACTCTCCTCCGA-3’ 
 
EP300  Forward primer: 5’- CTGCTACTGTGAATGAGACAGA-3’ 
Reverse primer: 5’- AGAACCAGGCAAAAACGCAC-3’      (867bp) 
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Hprt1 Bought from Qiagen   
Product: Hs_HPRT1_1_SG QuantiTect Primer Assay 
Product no.249900 
Cat.no. QT00059066 
 
Table 9 Reaction system used for realtime PCR 
Gene  1× run (μL) 
 
αSMA 
FN 
Col-I 
EP300 
cDNA 1 
Forward primer (10μM) 0.2 
Reverse primer(10μM) 0.2 
Sybr Green Master Mix 2× 5 
Nuclease-free water 3.6 
Total Volume 10 
 
Gene  1× run (μL) 
 
 
Hprt1 
cDNA 1 
Primer (10μM) 1 
Sybr Green Master Mix 2× 5 
Nuclease-free water 3 
Total Volume 10 
 
Table10 Program used for real time PCR 
Step Temperature (°C) Duration Cycles 
Polymerase activation 95 20 second Hold 
Denature 95 3 second  
40 Anneal/Extend 60 30 second 
 
2.2.7 Western blot 
For isolation of protein, cells in culture were washed three times with ice-cold PBS and lysed 
on ice with lysis buffer prepared by ourselves with freshly added PMSF for 30min. Cells were 
subsequently collected in a 1.5ml Eppendorf tube by scraping with a cell Scraper. Then the 
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liquid was resuspended with a syringe for 20 times and centrifuged at 15,000 g, 4 °C for 20 
minutes. The supernatant was transferred to a second labled Eppendorf tube and protein 
concentration was determined with a BCA kit according to the manufacturer’s instructions. If 
the proteins were not to be used immediately, samples were stored at -80 °C. 
For western analysis, certain amounts of proteins (5-10μg) with loading dye were boiled at 
95 °C for 5 minutes and loaded onto SDS-PAGE gels. Samples were run in the running buffer 
for 10min, 75V constant, then 90min, 135V constant (12% gel). The transfer of proteins from 
the gel to a Nitrocellulose membrane was carried out by a semidry transfer system. A 
sandwich model was made by soaking CHR blotting paper in Anode buffers I, Anode buffer 
II and Cathode buffer with membrane and gel. The semidry electrophoretic transfer was 
carried out for 60 minutes at 35V, 500mA. Then Membranes were blocked in 5% non-fat 
milk in Tris-buffered saline (TBS, 10 mM Tris, 10 mM NaCl) for 1h at room temperature. 
Subsequently washed and incubated with first antibody overnight at 4°C. Immunodetections 
were done with the corresponding secondary antibodies. ECL (Roche) and ImageQuant LAS 
4000 mini was used for visualization. The densitometric analysis was done by using Image J 
software. 
For large molecular weight proteins, such as FN, Col-I and EP300, 6% SDS-PAGE gel and 
PVDF membrane were used. The transfer of these proteins to PVDF membrane was done by 
using a wet-transfer system. And the wet electrophoretic transfer was carried out at room 
temperature for 4 hours at 150mA, 45V. For Col-I, the western was done at native condition. 
All the other steps were the same as mentioned above. 
For stripping, membranes were put into the stripping buffer for 10 minutes at room 
temperature, washed with PBS three times and blocked with 5% milk for 60 minutes before 
incubating with another primary antibody. 
The primary antibodies and the dilution ratios used were GAPDH (Sigma, 1:5000), EP300 
(Abcam, 1:500), αSMA (Acris, 1:1000), FN (Sigma, 1:500), α-tubulin (Sigma, 1:5000), 
pAKT (Abcam, 1:5000) , AKT(Cell signaling, 1:1000), pSTAT3 (Abcam, 1:100000), 
STAT3α (Cell signaling, 1:1000), pERK1/2(Cell signaling, 1:3000), ERK (Cell 
singaling,1:3000). The secondary antibodies used were HRP-conjugated goat-anti-rabbit 
(Vector, 1:5000), horse-anti-mouse (Vector, 1:5000). 
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2.2.8 ELISA Assay 
Col-I and FN are secreted protein, in order to analyze the secretion of them, the supernatant 
was collected as showed before. Subsequently, the media was condensed with Amicon Ultra-
10 centrifugal filter (Merck Millipore, MA, USA) and ELISA assay was performed to test the 
secretion of Col-I and FN. Results was normalized to cell numbers. Briefly, condensed media 
were coated in a 96 well microtiter plate ( Immunoplates MaxiSorp C 96, invritogen, ) at 4°C 
overnight, then wells were blocked with 3% BSA for 1 hours,  after washing three times with 
PBST, first antibody was incubated, then HRP conjugated secondary antibody was incubated. 
At Last TMB liquid were added to each well and signal was detected at 370 nm with a plate 
reader. 
2.2.9 Cells cultured on coverslips 
The 0.22×0.22 mm glass coverslips were soaked in 70% ethanol for at least 2 hours before 
using. Then one coverslip was placed over the bottom of each well of the 6-well plate with 
clean tweezer. After that, open the lid of the 6-well plate and put it into the cell culture hood, 
air dry for 30 minutes with the UV light on. Subsequently, stable EP300 down regulation cells 
and control group cells were seeded onto the coverslips at a concentration of 5×10
4
 for 48 
hours before the morphology was checked. 
2.2.10 Proliferation assay 
Stable EP300 knockdown PSCs and corresponding control PSCs were seeded in 96-well 
plates at 4×10
3 
per well.  24 hours later, serum free overnight, and fresh complete medium 
was added.  Then at the time point 24 h, 48 h, 72h, the proliferation of the cells was tested by 
resazurin assay. For conditioned medium treatment, 8×10
3
 Bxpc-3 or Panc-1 cells were 
seeding in 96 well plates, 24 hours later, serum free overnight, and conditioned medium were 
added. Then at the time point of 72h, the proliferation of the cells was tested by resazurin 
assay. Briefly, resazurin solution was added to each well, and make sure the final 
concentration of resazurin is 20µg/mL. Then the plates were incubated at 37°C for 2 hours 
and the fluorescence was recorded using FLUOstar Galaxy system. Ex=544 nm, Em=590 nm. 
2.2.11 Drug cytotoxicity assay 
The same number of cells was seeded and the same treatments were done as proliferation 
assay. It’s just that after serum free overnight, different concentrations of gemcitabine were 
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added to the cells in complete medium. 72 hours later, cell numbers were tested by resazurin 
assay as described above. For medium treatment drug sensitivity assay, complete medium was 
changed to conditioned medium during the experiment. All the other steps were the same. 
2.2.12 Migration assay  
HTS Transwell-96 well plate (Corning) with a pore size of 8 µm was used to do the migration 
assay.  Briefly, 1.2×10
4 
PSCs were added in serum-free medium in the upper layer. The lower 
layer was filled with complete medium, 48 hours later, cells on the bottom surface of the 
upper layer were detached and counted using resazurin assay. In the inhibitor treatment 
experiment, both the upper layer and the lower layer contains 20 µM DMSO or 20 µM U0126 
during the whole experiment. 
2.2.13 Conditioned media collection 
Control PSCs and stable EP300 knockdown PSCs were grown to 70% to 80% confluence in 
175 cm
2
 flasks in IMDM/10%FBS.  Then the media were changed to serum free IMDM and 
cells were cultured for 48h. Media were collected, centrifuged at 3,000 for 15min, condensed 
by Amicon Ultra centrifugal filter and protein concentration was tested by BCA kit. Then 
they were aliquoted and store at -80 °C until use. The same protein concentration media from 
control PSCs and stable EP300 knockdown PSCs were used for medium treatment assay. 
2.3 Statistic analysis 
All experiments were done three or more times. Data were shown as mean ± standard error 
mean. Two-tailed Student’s t test was used to make comparisons between different groups. 
Significant difference was defined differently based on different experiments. Statistical 
analysis was done using Excel.  
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3 Results 
3.1 siRNA transient knockdown of EP300  
To study the gene functions of EP300, siRNA was used knockdown EP300 in PSCs. 24 hours 
post transfection, quantitative RT-PCR results showed that the mRNA expression of EP300 
was reduced by 77.7%±0.04% compared to control (Fig. 7A). Western result verified that the 
protein expression of EP300 was reduced correspondently 48 hours after transfection (Fig. 
7B).   
 
Figure 7. siRNA transient knockdown of EP300. A.24 hours after knockdown, cells were collected and qRT-
PCR was used to analyze EP300 gene expression.  Hprt1 was used as control. The data represented the mean and 
SD of three independent experiments,*, P<0.05; B. 48 hours after knockdown, EP300 protein expression of 
PSCs was analyzed by western blot, GAPDH was served as loading control. 
3.2 Transient knockdown of EP300 affects the expression of PSCs’ activation markers 
To determine the activation status of PSCs after EP300 knockdown, the expression of α SMA, 
FN and Col-I, which were activation markers of PSCs, were studied in both mRNA and 
protein levels. FBS activates PSCs and PSCs were cultured in complete medium during the 
whole experiment, therefore PSCs were in an activation stimulation environment during the 
whole process. And, mRNA was collected 24 hours post knockdown and protein was 
collected 48 hours post knockdown. The expression of αSMA didn’t change in both mRNA 
and protein levels. FN was down regulated in both levels (Fig. 8A, Fig. 8B). However, Col-I 
expression was increased at mRNA level, but reduced at the protein level. For the western 
results of Col-I, the antibody showed two major bands, the lower bands were 170 kDa for pro-
collagen and the upper bands were 270 kDa for the dimer. 
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Figure 8. Effects of EP300 down regulation on the expression of activation markers of PSCs. A.24 hours after 
knockdown, cells were collected and qRT-PCR was used to analyze specific gene expression.  Hprt1 was used as 
control. The data represented the mean and SD of three independent experiments,*, P<0.05; **, P<0.01. B. 48 
hours after knockdown, selected protein expression of PSCs was analyzed by western blot, GAPDH was served 
as loading control.  
3.3 Transient knockdown of EP300 reduces the secretion of FN and Col-I by PSCs 
Since that FN and Col-I are extracellular matrix proteins secreted by activated PSCs, Elisa 
was used to analyze the protien expression levels of them in the conditioned medium. And the 
results showed that there were less amount of Col-I and FN in the experiment group’s 
conditioned medium (CM) than in the control group’s CM. Statistically, Col-I secreation was 
decreased by 50% ±0.05% (Fig. 9A),  FN secreation was reduced by 32%±0.03% (Fig. 9B) 
 
Figure 9. Transient knockdown of EP300 reduces the secretion of FN and Col-I by PSCs. 48 hours after 
knockdown, cells were cultured in serum-free medium for another 48 hours and the condioned medium was 
collected and condensed, subsequently, ELISA was used to analyze the secretion of Col-I and FN by PSCs. 
Results was normalized to cell numbers. Figure A and B respectivey showed the ELISA assay results of Col-I 
and FN.*,P<0.05. 
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3.4 Generation of EP300 stable knockdown cell lines 
CRISPR/Cas9 gRNA was used to generate stable EP300 knockdown cell lines and scramble 
gRNA plasmid transfected cells were served as control. After antibiotic selection, stable 
knockdown cell line and corresponding control cell line were generated. Figure 10A was the 
result of T7 endonuclease I (T7E1) assay, which showed that there was cleavage in the DNA 
sequence in gRNA treated cells, so our targeting was successful. Figure 10B showed that 
EP300 protein expression was highly down regulated in gRNA treated group. 
 
Figure 10. Generation of EP300 stable knockdown cell lines. A. After antibiotic selection, cells were cultured 
for 24h, then the genome DNA was extracted for T7E1 assay. PCR products of target regions are shown by 
black arrowhead. Colored arrowheads indicate cleaved products by Cas9. B. Cells were cultured for 48h, then 
lysis buffer was used to collect protein from them, western results showed that EP300 was downregulated. 
3.5 Stable EP300 knockdown inhibits FN and Col-I synthesis by PSCs 
After obtaining EP300 stable knockdown cell lines, cell lysis and conditioned medium were 
collected to test FN and Col-I expression inside and outside the cells. Same results were 
obtained as transient knockdown, compared to the control, both the synthesis and the 
secretion of FN and Col-I was reduced in the EP300 down regulation group. Figure 11A 
showed the western results of cell lysis, FN and Col-I expression was declined significantly. 
For the western results of Col-I, as mentioned before, the lower bands were for pro-collagen 
and the upper bands were for the dimer. Figure 11B showed the ELISA results of the 
conditioned media, Col-I secretion was decreased by 47%±0.07% and FN secretion was 
reduced by 25%±0.03% statistically compared to the control. 
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Figure 11. Stable EP300 knock down inhibits FN and Col-I synthesis by PSCs. A. EP300 downregulation PSCs 
and corresponding control PSCs were grown for 48 hours, then cell lysis was collected, subsequently, specific 
protein expression of PSCs were tested by western blot. The results showed that FN and Col-I expression was 
downregulation when EP300 is knockdown. B. For medium collection, cells were seeding in a 6-well plate for 
24 hours, so they could reach 80%-90% confluence, then serum free for 48 hours before media collection. Media 
was condensed by Ultra filter from Merck Millipore before used for ELISA assay and results were normalized to 
cell number.  *, P<0.05. 
3.6 EP300 downregulation induces phenotype changes in PSCs 
After seeding stable EP300 downregulation cells and corresponding control cells on glass 
cover slips for 48 hours, cell morphology was observed.  A number of cells in the EP300 
down regulation PSCs showed exactly fibroblast cell morphology, thin, long and spindle like 
with expanded cytoplasm, as indicated in Figure 12B with red arrow. However, in the control 
group, most of the PSCs were round shape like and tend to grow together, as showed in 
Figure 12A with blue arrow. We randomly selected 10 different fields of visions in both 
groups, took pictures and counted cells in them. The EP300 downregulation group has 
16.7%±3.3% of cells possess a myofibroblast-like morphology, but in the control group only 
5.4%±0.3% of cells were fibroblast-like (Fig. 12C). 
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Figure 12. The morphology changes of pancreatic stellate cells. Control PSCs and stable EP300 knockdown 
PSCs were grew separately on glass slides for 48 hours, then cell morphology were observed. A.The 
morphology of control PSCs. Cells were round shape like and tend to grow together, as showed with blue arrow. 
B. The morphology of EP300 knockdown PSCs. Some cells showed fibroblast-like shape, thin, long with 
expanded cytoplasm, as indicated with red arrow. Original magnification 200×. C. Ten different fields of visions 
were randomly selected in both groups and cells were calculated. The percent of cells that possess 
myofibroblast-like phenotype in each group were showed. *, P<0.01. 
3.7 EP300 down regulation doesn’t affect the proliferation of PSCs 
To determine whether EP300 knockdown will influence the proliferation of PSCs. The 
proliferation of stable EP300 knockdown cells and corresponding control group cells were 
tested at 24h, 48h and 72h by resazurin assay. Figure 13 showed that EP300 knockdown had 
no influence on the proliferation of PSCs. 
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Figure 13. EP300 knockdown doesn’t affect the proliferation of PSCs. The stable EP300 down regulation cell 
line and corresponding control cell line were cultured in 96 well plates. Cell proliferation was tested at time 
point 24h, 48h and 72h by resazurin assay. The data represented the mean and SD of three independent 
experiments performed in 8 replicates.   
3.8 EP300 down regulation increases the drug sensitivity of PSCs  
To study the drug sensitivity of cells after knockdown, stable EP300 down regulation cells 
and control group cells were treated with different concentrations of gemcitabine for 72 hours. 
As showed in Figure 14: at the concentration of 0.01µM, 60.1%±0.02% of the cells were still 
alive in the control group after drug treatment. However, only 34.3%±0.02% cells were still 
alive in the knockdown group. At the concentration of 0.1µM, 43.2%±0.01% of the cells were 
still alive in the control group, but only 28.8%±0.01% of the cells were alive in the 
experiment group. 
 
Figure 14. EP300 knockdown increases the drug sensitivity of PSCs. Control group and knockdown group cells 
were treated with different concentrations of gemcitabine for 72h in complete medium, and then the cell 
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numbers were tested by resazurin assay. These data represented the mean and SD of three independent 
experiments performed in 8 replicates.*, P<0.01. 
3.9 EP300 down regulation promotes PSCs migration  
When PSCs are activated, they will begin to migrate and promote the migration of pancreatic 
cancer cells simultaneously [75, 151]. Hence, after obtaining the stable knockdown PSCs, to 
investigate the modulation of metastasis by EP300, the migration of the PSCs was studied 
using trans-well plates. Results showed that EP300 down regulation increases PSCs migration 
significantly. Around a 3.5 fold increment in migration was observed. 
 
Figure 15. EP300 down regulation promotes cell migration significantly. Cells were seeded in a 96 trans-well 
plates according to the protocol, 48 hours later, cells that migrated through the membrane were counted. As 
shown above, EP300 down regulation increased the migration of PSCs more than 3.5 fold compared to the 
control. *, P< 0.05. 
3.10 EP300 promotes the migration of PSCs through activation of ERK pathway 
Totally, there are three pathways that are highly related to cell migration, which are PI3K 
pathway, JAK-STAT pathway and ERK pathway. To find out which pathway is related to 
EP300 induced migration, the activation status of the three pathways were tested. The 
expression of functional protein phospho-STAT (p-STAT) of JAK-STAT pathway was 
reduced (Figure 16A) compared to the control group and the expression of functional protein 
phospho-AKT (p-AKT) of PI3K-AKT pathway was not changed compared to the control 
(Figure 16B). Activation of ERK pathway is the result of phosphorylation of ERK1 and 
EKR2 (ERK1/2) on their serine and threonine residues by MAP kinase kinase. Figure 16C 
showed that EP300 down regulation led to phosphorylation of ERK1/2 even to 48 hours. 
EP300 chemical inhibitor C646 got the same effects (Fig.16D). However, 48h treatment with 
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C646 made the cells express less total ERK1/2, which means that the inhibitor is toxic to the 
cells in long time treatment. 
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Figure 16. EP300 downregulation induces migration of PSCs through ERK pathway. A. Stable EP300 
knockdown cell line and control group cell line were cultured for 24h or 48h. Then total cell lysates were 
collected. The functional protein expression of JAK-STAT pathway was checked by western blot and the result 
were quantified by densitometry. B. Same experiment was done as in Figure 16A, except that the functional 
protein expression of PI3K-AKT pathway was checked. C. Stable EP300 knockdown cell line and control group 
cell line were cultured for 12h, 24h, 36h or 48h. Then total cell lysates were collected. The activation of ERK1/2 
was determined by western blotting. And densitometry was used to quantify the relative expression of pERK1/2. 
D. Results from EP300 down regulation were also verified by treating normal PSCs with inhibitor C646 at the 
concentration of 20µM for different time points. The relative expression of pERK1/2 was quantified by 
densitometry. *, P< 0.05, n≥3. 
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3.11 EKR pathway is required for EP300 induced migration 
In order to find out whether EKR pathway is essential for EP300 induced migration, a 
chemical inhibitor-U0126 was used in the current experiment. U0126, a highly selective 
inhibitor for both EKR1 and ERK2, can block the activation of EKR pathway. As showed in 
Figure 17, when cells were treated with U0126, the migration of EP300 down regulated group 
was decreased dramatically to the control level. 
 
Figure 17. ERK pathway is required for EP300 induced migration of PSCs. U0126 blocks activation of ERK1/2.  
Cells were treated with 20µM DMSO or 20µM U0126 during the migration assay, 48 hours later, cells that 
migrated through the membrane were counted. *, P<0.01, n≥3. 
3.12 EP300 down regulation increases the proliferation effect PSCs have on pancreatic 
cancer cells 
To determine whether reduced expression of EP300 in PSCs will affect the proliferation 
effect PSCs have on pancreatic cancer cells, conditioned medium (CM) was collected from 
control group PSCs and EP300 knockdown PSCs to treat pancreatic cancer cells. At 72h, CM 
from control group PSCs increased the proliferation of Bxpc-3 cells by 33%±8% compared to 
serum free (SF) medium, however, CM from EP300 knockdown PSCs increased the 
proliferation of Bxpc-3 cells by 57%±6% compared to SF medium (Figure 18A). For Panc-1 
cells, the increment in proliferation by CM from control group is 62%±6%, by CM from 
EP300 knockdown group is 89%±5% compared to SF medium (Figure 18B).  
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Figure 18. EP300 down regulation increases the proliferation effect PSCs have on pancreatic cancer cells. 
Conditioned medium from control group PSCs (CM) and EP300 knockdown PSCs were collected and used for 
the treatment for pancreatic cancer cells.  After 72 hours treatment with CM, the proliferation of pancreatic 
cancer cells was tested by resazurin test. A, showed the results of Bxpc-3 cells, B showed the results of Panc-1 
cells. *, P<0.01; **, P<0.001; n≥3.  
3.13 EP300 down regulation in PSCs inhibits effects of chemotherapy on tumor cells 
In order to study whether EP300 down regulation in PSCs will influence the chemotherapy on 
tumor cells, Bxpc-3 and Panc-1 cells were treated with different concentration of gemcitabine 
for 72 hours, together with serum free medium, or conditioned medium (CM) from control 
PSCs or conditioned medium from EP300 knockdown PSCs. For Bxpc-3, cells treated with 
knockdown CM were more drug resistant than cells treated with control group CM. For Panc-
1, there was no significant difference between different treatment groups. 
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Figure 19. EP300 down regulation in PSCs inhibits effects of chemotherapy on tumor cells. Bxpc-3 and panc-1 
were treated with different concentration of gemcitabine for 72 hours, together with serum free medium (SF) or 
conditioned medium (CM) from control group PSCs or conditioned medium from knockdown PSCs, then cell 
proliferation was tested. *, P<0.05, n≥3. 
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4 Discussions 
The activation of PSCs is a phenomenon that can’t be ignored in pancreatic ductal 
adenocarcinoma, which makes a great contribution to the stroma formation in this cancer. 
Researchers have found that growth factors, cytokines, such as TNFα, TGFβ, PDGF, 
interleukin 1, interleukin 6 [63, 76, 84, 152-154], ethanol and oxidant stress [86] can activate 
pancreatic stellate cells. However, little research has been done on how a gene will influence 
the activation of PSCs. PSCs’ activation process involves proliferation, migration, enhanced 
production of extracellular matrix proteins and a phenotypic transition towards myfibroblasts. 
EP300, as mentioned above, is a histone acetyltransferases and plays a very important role in 
regulating cell proliferation and differentiation and it has been implicated in cancer. So in this 
article, we explored how EP300 down regulation will affect the activation of PSCs and how 
that will influence the communications between PSCs and pancreatic cancer cells. 
As mentioned before, activated PSCs are the main contributor to the stroma formation in 
pancreatic cancer. Since when PSCs were activated, it began to excrete ECM proteins, 
including FN, Col-I and so on [152]. These ECM proteins were also the activation makers of 
PSCs. Another important activation maker of PSCs is α SMA [153]. Transient knockdown of 
EP300 resulted in less synthesis of FN and Col-I in PSCs, but α SMA expression was not 
changing. And the expression of FN reduced in both mRNA and protein levels, however, Col-
I expression increased in mRNA level, decreased in protein level, it is possible that some 
miRNA working in the translation process of Col-I. Since EP300 lower expression has no 
influence on the expression of α SMA, it is unreasonable to say that EP300 knockdown 
deactivate PSCs. The conclusion we could draw from the results is that EP300 down 
regulation reduces the ECM synthesis of PSCs. And further ELISA experiments verified that 
the secretion of FN and Col-1 were also decreased in the conditioned medium when EP300 is 
knockdown. 
CRISPR/Cas9 is a gene editing technique that can target and modify DNA with extremely 
high accuracy. It can be used to generate knock-out cells or animals. To better understand the 
role of EP300 in activated PSCs, this technique was used to intervene in the expression of 
EP300. After antibiotic selection, T7E1 assay result showed that there was cleavage on the 
genome DNA, so targeting was successful. However, western results showed that there was 
still some protein left in the experiment group. It is possible that this is a heterozygous 
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knockout. Similarly, Wang [155] used CRISPR/Cas9 to mediate heterozygous knockout of 
the gene CHD8, there were still CHD8 proteins left in the knockout groups. Shetty [156] 
revealed the same western result for heterozygous knockout of the gene CDH8. It is also 
possible that EP300 is essential for the survival of cells, so EP300 knockout cells couldn’t be 
obtained. As showed by previous study, EP300 and CBP knockouts are early embryonic 
lethal [147]. Since down regulation of EP300 is enough to study of the gene functions of 
EP300, and during all the following experiments in this article, the lower expression of EP300 
was always existed in the knockdown group, so no further experiment was done to clarify this 
problem. The reduced ECM synthesis was also proved in stable EP300 down regulation cell 
lines. 
We accidentally seeded control group PSCs and EP300 knockdown PSCs on glass cover slips 
and find that EP300 knockdown PSCs possess more percent of fibroblast-like cells than the 
control group. It has long been known that the behavior of Hepatic stellate cells (HSCs) is 
influenced by the interaction between HSCs and matrix components [157]. For example, 
Sohara [158] showed that hepatic stellate cells were de-activated by growth on matrigel. PSCs 
and HSCs have a lot in common. Jesnowski [69] found that immortalized PSCs could be 
deactivated by matrigel and N-acetylcysteine. In the current study, cells were seeded on glass, 
an unfavorable basement substrate, which will also interact with the cells. Current results of 
morphological changes indirectly proved that EP300 knockdown PSCs were more active. 
Absence of EP300 induces cellular phenotypic changes has been shown before, Krubasik 
[159] found that colon carcinoma cell lines loss of EP300 obtained aggressive cancer 
phenotypes. 
The expression of EP300 influences cell proliferation has been studied before. For example, 
researchers found that lower expression of EP300 reduced the proliferation of dental pulp 
cells [160], acute myeloid leukemia cells [161] and prostate cancer cells[162].  Despite that, it 
is also found EP300 knockdown inhibits apoptosis in human breast cancer cells [141]. In the 
present study, we showed that EP300 down regulation has no effect on the proliferation of 
PSCs. Scientists have proved that same gene can play very different roles in the cell [163]. 
PSCs are not regular cells, they changes from a quiescent fat storing cells to a highly 
proliferate cells during cancer, so EP300 down regulation doesn’t affect the proliferation of 
PSCs is reasonable. 
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Another observation in the current study was that EP300 lower expression increased the drug 
sensitivity of PSCs. Similarly, Bourguignon [164] found that up regulation of EP300 was 
related to chemo-resistance in breast cancer.  And Ono[165] clarified that EP300 inhibition 
enhanced the effect of gemcitabine through E2F1 activation in pancreatic cancer.  
What’s more, how EP300 down regulation affectes the migration of PSCs was studied. In 
previous studies, Mees [166] investigated genetic and epigenetic data found that EP300 is a 
miRNA regulated metastasis suppressor gene in pancreatic ductal adenocarcinoma. Zhou [167] 
studied breast cancer and verified that by targeting EP300, miR-106b ~25 cluster increased 
motility and invasion of these cancer cells. Krubasik [159] found that down regulation of 
EP300 in colon carcinoma cell lines increased their migration. In the present study, our results 
showed that lower expression of EP300 significantly increased the migration of PSCs. And to 
elucidate the mechanisms involved, three pathways were studied: PI3K pathway, JAK-STAT 
pathway and ERK pathway, which were verified by formal studies highly related to cell 
migration [168-172]. The results showed that EP300 lower expression activates ERK pathway. 
And treating PSCs with C646, a chemical inhibitor of EP300, has the same effects within 48h. 
Except that at the time point of 48 hours, C646 has begun to show toxic effects on cells. 
Furthermore, inhibition of ERK with U0126 abolished EP300-induced migration. These 
evidences for the first time showed that EP300 could manipulate cell migration through ERK 
pathway. 
Finally, how EP300 down regulation in PSCs will affect the communications between PSCs 
and pancreatic cancer cells was analyzed. In the formal study, Hwang [110] found that 
conditioned medium from PSCs increased the proliferation, migration and invasion of 
pancreatic cancer cells. Vonlaufen [111] proved that a significant interaction between PSCs 
and pancreatic stellate cell is existed and pancreatic cancer cells recruit stromal cells to build 
an environment that promotes cancer progression. In this article, we showed that lower the 
expression of EP300 in PSCs increases the proliferation effect PSCs have on pancreatic 
cancer cells, which means that EP300 down regulation makes PSCs more active and more 
supportive for pancreatic cancer cells. 
At last, how lower expression of EP300 in PSCs will influence the effects of chemotherapy on 
pancreatic cancer cells were examined. Conditioned media from PSCs have been proved to be 
able to reduce pancreatic cancer cell sensitivity to gemcitabine and radiation therapy [111]. 
And in an orthotopic model of pancreatic cancer, it has been shown that animals injected with 
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both PSC and PDAC cells were more resistant to radiation and gemcitabine treatment than 
animals injected with PDAC cells alone [110]. Our study showed that conditioned media from 
PSCs can protect Bxpc-3 cells from chemotherapy, and when EP300 is knockdown in PSCs 
the effect is much higher. However, for Panc-1 cells, conditioned media from control PSCs 
and EP300 knockdown PSCs have no influence on the drug sensitivity of Panc-1 cells. Why 
there is a difference between different pancreatic cancer cell lines need further study. 
In conclusion, this study demonstrated evidence that down regulation of EP300 increases the 
activation of PSCs and makes PSCs are more supportive for pancreatic cancer cells, but it 
reduces the ECM synthesis by PSCs. Moreover, we firstly showed that EP300 manipulated 
cell migration through ERK pathway. And our results support the concept that targeting 
stromal cells can influence the interactions between stromal cells and pancreatic cancer cells, 
which may become an important therapeutic approach in pancreatic cancer. 
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Part II: Pancreatic Stellate Cells and Drug Resistance in 
Pancreatic Cancer 
1 Introduction 
1.1 Pancreatic cancer 
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy and ranked the 
fourth leading cause of cancer-related death in both Europe and USA [1]. It is associated with 
its rapid tumor progression and metastasis [2, 3], it’s highly resistant to both chemo and 
radiation therapy [4, 5]. For 2017, it is predicted that 87,400 people will dye of pancreatic 
cancer in the European countries and 44,090 people will dye of pancreatic cancer in the USA 
[6, 7]. Despite so many years have passed, the survival rate of pancreatic cancer has not 
improved and no cure treatment has been found. As an increasing number of people in the 
Europe have been diagnosed with pancreatic cancer (showed in Figure 1) and most of them 
die within 6 months, it is very crucial to find efficient ways to fight against it.   
 
Figure 1. Age-standardized EU male and female cancer mortality rate trends in quinquennia from 1970- 1974 to 
2005-2009 plus the year 2012 and predicted rates for 2017 with 95% prediction intervals. Pancreas (triangles) in 
both men and women [6]. 
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1.2 Treatments for cancer  
Cancer treatments vary between different hospitals and different patients, which is largely 
based on experience. Generally, there are three types of treatment: surgery, radiotherapy and 
drugs. These treatments may be used alone or in combination. Surgery treatment usually 
applies for early stage patients and specific cancer types. For example, it is the mainstream 
treatment for primary stage liver cancer patients and the survival rate has improved a lot after 
surgery, sometimes ever curable [8]. Radiotherapy is the most utilized treatment for cancer, 
and there exist a suggestion that nearly 50% of all cancer patients should do radiation [9]. 
Indeed, almost all types of cancer could receive radiation therapy, such as breast cancer, lung 
cancer, melanoma, lymphoma, stomach cancer, colon cancer and so on. Drug treatment 
contains chemotherapy, which intend to use drugs to destroy cancer cells but not to damage 
healthy cells. These used drugs usually intervene the DNA synthesis, replication or 
transcription process of the cancer cells, such as Mercaptopurine, Melphalan and Cispaltin. 
Then how do the treatments mentioned above work on PDAC? In the past ten years, 
pancreatic surgery has improved a lot. The surgery process is safe and after surgery the 
morbidity and mortality rates are the same as other gastrointestinal cancer [10]. However, 
since it is hard to diagnosed pancreatic cancer in the early stage, only 20% of the patients are 
suitable for surgery, and the prognosis of pancreatic cancer has not changed for decades, the 
overall survival rate of PDAC has not improved. Chemoradiation therapy is commonly 
chosen for cancer, when the tumor is unresectable. However, pancreatic cancer is highly 
resistant to traditional chemo and radiation therapy, which makes it more difficult to cure. 
Right now, the standard treatment for pancreatic cancer patients is drug treatment, the use of 
gemcitabine, which has modest benefit and the overall survival rate has not improved much 
after the treatment [11, 12]. Therefore, it is urgent to overcome the drug resistant problem in 
pancreatic cancer and find new therapies for it. 
1.3 Mechanisms of drug resistance in cancer 
The concept of drug resistance comes from antibiotics. After scientist Alexander Fleming 
discovered penicillin in 1928, penicillin was used to treated infections [13]. But as years pass 
by, the effect of penicillin was reduced on some patients, and scientist found out that it is 
because bacteria developed drug resistance to penicillin. Since then the same drug resistance 
problem began to occur in other diseases, such as cancer. Resistance to treatment is a 
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frustration issue and a lot of factors contribute to that. In cancer, patients can become drug 
resistant for general two reasons：(1) Host factors, such as poor absorption, low tolerance, or 
rapid metabolism of a drug; (2) Gene mutations in cancer cells, some gene alterations may 
cause cells insensitive to drugs [14]. In the following paragraph, we will discuss the biological 
mechanisms of drug resistance in cancer. 
1.3.1 Multidrug resistance proteins and drug resistance in cancer 
In the field of drug resistance, multidrug resistance proteins are famous, which play important 
roles in transport drugs out of the cell. Generally, there are two subfamilies of them: (1) 
Multidrug resistance protein (MDR) family, it consists of MDR1 and MDR2 or alternative 
names ABCB1 and ABCB2; (2) Multidrug resistance-associated protein (MRP) family, it has 
6 members: MRP1, MRP2, MRP3, MRP4, MRP5 and MRP6 or alternative names ABCC1, 
ABCC2, ABCC3, ABCC4, ABCC5 and ABCC6 [15]. They are all the members of human 
ATP-binding cassette (ABC) transporters and expressed in the epithelial cells of the liver and 
the intestine [16]. Normally, they pump harmful molecules out of cell to protect the body. 
However, when treating cancer patients with drugs, the expression of them will cause poor 
clinical outcome. For example, MDR1 and MRP1 have been found highly expressed in many 
drug resistance cancers [17, 18]. And treatment with doxorubicin in lung cancer has been 
discovered highly activated MDR1 expression [19]. In addition, high-level expression of 
multidrug resistance-associated protein 1 has been found associated with poor clinical 
outcome in neuroblastoma [20]. 
               
Figure 2. Model of substrate transported by multidrug resistance protein. A. The magenta substrate enters the 
membrane and moves in the transporter. B. The yellow ATP binding to the transporter and causes a structure 
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change of it. The magenta substrate was pumped out of the membrane by the transporter [21]. 
1.3.2 Gene mutations and drug resistance in cancer 
Drug resistance is still a major problem existed in cancer chemotherapy. Scientist found that 
certain gene mutations are related to chemo-resistance in cancer. For instance, a clinical 
research showed that leukemia patients with p53 gene mutations are more resistant to 
chemotherapy than those without p53 mutations [22]. In leukemia, clinical resistance to drug 
therapy was found to be caused by BCR-ABL gene mutation or amplification [23]. In breast 
cancer, specific p53 mutations were found related to resistance to doxorubicin [24]. In lung 
cancer, researcher showed that T790M mutation in EGFR kinase can cause drug resistance 
[25] and mutations in KRAS are related to drug resistance to gefitinib and erbotinib [26]. 
1.3.3 Epigenetic modifications and drug resistance in cancer 
There are mainly two types of epigenetic modifications: DNA methylation and histone 
modification. DNA methylation is important for the development of human beings. It often 
happens at the GC rich area by adding methyl group to cytosine. When the CpG-rich 
promoter is highly methylated, the transcriptional initiation of the gene will be stopped. DNA 
methylation plays an important role in tissue-specific gene expression and this epigenetic 
methylation patters on DNA are inheritable [27-29]. Histone modification includes acetylation 
and methylation. It can regulate the expression of genes by changing the structure of 
chromatin [30]. During cancer, these normal epigenetic modification patters mentioned above 
are disrupted, which will cause the highly expression of oncogenes by low methylation or the 
silence of tumor suppress genes by high methylation. Furthermore, it is found that these 
epigenetic changes are associated with drug resistance in cancer. For example, Kantharidis 
[31] showed that the acquired drug resistance in leukemia is related to altered methylation of 
human MDR1 gene. Chen [32] discovered that chemo-sensitivity to temozolomide is 
regulated by DNA methylation and histone acetylation in melanoma. A study of Steele [33] 
found that drug sensitivity was improved by inhibiting DNA methylation and histone 
acetylation together in ovarian cancer. 
1.3.4 Epithelial-mesenchymal transition (EMT) and drug resistance in cancer 
Epithelial-mesenchymal transition is an important process during embrogenesis. In cancer, it 
plays a crucial role in tumor invasion and metastasis. When cancer cells go through EMT, 
they will lose their cell-cell contacts and begin to migrate and invade, their morphology may 
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also change. In lung cancer, scientist showed that the acquired gefitinib resistance in cancer 
cells is highly associated with EMT process and when EMT process is reversed, the 
sensitivity to gefitinib is restored [34]. In liver cancer, researcher found that 
microRNA216a/217 induces EMT of cancer cells, which promote drug resistance of these 
cells [35]. In bladder cancer, EMT was showed to regulate drug resistance and muscle 
invasion /metastasis in this cancer [36]. Furthermore, Saxena [37] found that EMT contributes 
to drug resistance by up regulating ABC transporters. 
1.3.5 Cancer stem cells and drug resistance in cancer 
Stem cells are cells that can produce more stem cells and generate mature cells of certain 
types [38]. In human beings, they generally have two types: embryonic stem cells and adult 
stem cells, which function as a repair system. The concept of cancer stem cells started in the 
1990s [39] and gradually accepted worldwide and began to influence the research area of 
cancer. In tumor tissue, cancer stem cells only possess a very small part, around 0.1%-1%, 
and it varies among different tumors [40, 41]. There exists a hypothesis that it’s cancer stem 
cells that make cancer difficult to cure and it is believed that chemotherapy only kills most of 
the tumor cells, but leaves cancer stem cells along. Since stem cells have the ability to self-
renew and differentiate, cancer relapses [42]. As normal tissue stem cells are drug resistant, 
which is related to MDR transporters and detoxifying enzymes [43], it is reasonable to think 
that cancer stem cells are drug resistant and maybe with the same mechanisms. Liu [44] 
showed that cancer stem cells in glioblastoma are chemo-resistance. Ma [45] found that by 
expression of survival pathways, hepatocellular carcinoma cancer stem cells are drug 
resistant. Fillmore [46] discovered that breast cancer stem cells are resistant to chemotherapy. 
So, in the future, maybe targeting cancer stem cells could be a new therapy to fight against 
cancer. 
1.4 Strategies to fight against drug resistance in cancer  
There are generally two ways to overcome MDR caused drug resistance problem in cancer: 
First, develop anticancer drugs that don’t bind to ABC transporter, such as antimetabolites (5-
fluorouracil) [47]; Second, find nontoxic ABC transporter inhibitors. Till now, three 
generations of MDR inhibitors have been developed. The first generation inhibitor, such as 
verapamil, has unacceptable toxicity. The second-generation inhibitor, such as valspodar, has 
unwanted interactions with other proteins. The most promising inhibitor right now is the 
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third-generation inhibitor, such as tariquidar XR9576, which has high specificity and has 
shown promise in clinical trials [48]. 
Another common strategy to overcome drug resistance problem in cancer is the using of 
combined therapy. Different drugs may have different metabolisms and mechanisms of action, 
therefore using two different drugs together may result in synergistic effect. For example, in 
colorectal cancer, combined treatment of irinotecan and fluorouracil increased the survival of 
the patients [49]. In breast cancer, trastuzumab and docetaxel combined treatment has better 
effect in terms of survival rate, response rate and response duration compared to docetaxel 
treatment alone [50]. Combine treatment also has been shown to have superior effect in 
ovarian cancer [51]. However, sometimes, using two drugs simultaneously may result in 
antagonism, so it is important to choose the combination of the drugs. 
1.5 Mechanisms of drug resistance in pancreatic cancer 
In pancreatic cancer, the drug resistance problem can also impute to multidrug resistance 
proteins, gene mutations, EMT and pancreatic stem cells. For example, multidrug resistance 
proteins have been found expressed in pancreatic cancer [52]. The BRCA2 gene mutation has 
been shown related to drug resistance in pancreatic adenocarcinoma [53]. EMT has been 
proved made a contribution to drug resistance in pancreatic cancer [54]. Pancreatic stem cells 
have verified play a role in the acquisition of drug resistance in pancreatic adenocarcinoma 
[55]. Despite these common mechanisms, there are other mechanisms exist in pancreatic 
cancer that are related to drug resistance. 
1.5.1 Signaling pathways and drug resistance in pancreatic cancer 
Scientist found that abnormal regulation of certain signaling pathways is related to drug 
resistance problem in pancreatic cancer. For example, Arlt [56] showed that activation of NF-
κB confers resistance against gemcitabine in pancreatic cancer. NF-κB is an important 
regulator in control cell proliferation and cell survival in healthy cells. In cancer, the 
activation of NF-κB will stop cancer cells from apoptosis. PI3K/AKT pathway also has been 
found associated with drug resistance problem in pancreatic cancer [57]. And inhibition the 
activation of PI3K/AKT pathway increased the drug sensitivity of pancreatic carcinoma cells 
[58]. 
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1.5.2 Pancreatic stellate cells and drug resistance in pancreatic cancer 
In pancreatic cancer, for many years, researches have been focused on cancer cells to deal 
with the problem, which have largely failed. In recent decades, there has been a growing 
number of data suggest that tumor microenvironment plays an important role in the process of 
pancreatic cancer, and PDAC is especially stroma rich [59-63]. Pancreatic stellate cells 
(PSCs), which are activated during chronic pancreatitis and cancer, were found to produce 
extracellular matrix (ECM) proteins that comprise the pancreatic tumor stroma [64]. Both in 
vitro and in vivo evidence proved that pancreatic stellate cells play an important role in the 
process of the development of pancreatic cancer [65]. 
 
Figure 3. Drug resistance pathways in pancreatic cancer [66]. 
Furthermore, studies have shown that pancreatic stellate cells are highly related to the chemo-
resistance of pancreatic cancer. In an orthotopic model of pancreatic cancer, it has been shown 
that animals injected with both PSC and PDAC cells were more resistant to radiation and 
gemcitabine treatment than animals injected with PDAC cells alone [67]. And there is a 
hypothesis indicate that the role of PSC is to function as a barrier preventing chemo-drugs to 
be delivered to the tumor core [66]. Researchers found that the extensive fibrosis produced by 
PSCs result in significant intratumoural hypoxia and a self-perpetuating hypoxia-fibrosis 
cycle, which limits the drug delivery to tumor cells [68-71]. Conditioned media from PSCs 
have been proved to reduce pancreatic cancer cell sensitivity to gemcitabine and radiation 
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therapy [65]. The secretions of PSCs also have been shown to be able to decrease H2O2-
induced apoptosis and increase survival of pancreatic cancer cells, which makes cancer cells 
more drug resistant [72]. However, no study has ever been done on how PSCs will affect the 
drug sensitivity of different drug sensitive cancer cell lines and the mechanisms of how PSCs 
protect tumor cells from chemotherapy.             
1.6 Gemcitabine and pancreatic cancer 
The high resistance to chemotherapy of pancreatic cancer is really a frustration issue, which 
makes it more difficult to deal with. Right now, gemcitabine is the most effective drug that 
works on pancreatic adenocarcinoma and it is used as a standard treatment. As an analogue to 
cytosine, gemcitabine is incorporated into the DNA to block it from replication, which results 
in cell death. It was first synthesized by Eli Lilly Company in 1980s and approved by the 
FDA for the treatment for patients in 1996 [73]. However, the life quality of the patients and 
the survival rate of the patients have not improved much even after gemcitabine treatment, it 
has some success but the response rates are still low [74]. 
 
Figure 4. Structure of gemcitabine and cytosine 
The mechanisms of gemcitabine resistance have been well studied since it is the only 
effective drug for pancreatic adenocarcinoma. To understand the mechanism of gemcitabine 
resistance, we need to know the metabolism of gemcitabine. Generally, gemcitabine needs to 
go through 10 steps to work inside of the cell. The first step is transporting across the 
membrane, the second step is phosphorylating by enzyme and so on and the last step is imbed 
into DNA or RNA. Each step can influence the efficiency of gemcitabine. For example, the 
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first step, there are mainly two types of nucleoside transporters that are related to gemcitabine 
transport: the sodium-dependent type or concentrative type (CNT) and the sodium-
independent type or equilibrative type (ENT). The expression of human ENT1 has been 
demonstrated to associate with the survival time of the patients under gemcitabine treatment 
[75, 76]. And overexpression of human ENT1 increases gemcitabine response in pancreatic 
cancer [77]. 
Besides the nucleoside transporters mentioned above, some enzyme activities in between have 
also been proved highly related to gemcitabine resistance: (1) Downregulation of 
deoxycytidine kinase (dCK). dCK plays a pivotal role in gemcitabine activation, after entering 
of the cells, dCK phosphorylates gemcitabine to its monophosphate. (2) Up regulation of 
cytidine deaminase (CDA). Gemcitabine can be effectively inactivated by activation of CDA. 
(3) Up regulation of ribonucleotide reductase, ribonucleotide reductase plays a role in the 
synthesis of DNA. Ribonucleotide reductase consists of two subunits: M1 and M2, together 
these two subunits form an active heterodimer [78-80]. 
 
Figure 5. Metabolism and mechanisms of action of gemcitabine; 1: transprot across the cell membrane, 2: 
phosphorylation of gemcitabine by dCK and TK2, 3: deamination of gemcitabine by dCDA, 4: deamination of 
gemcitabine by dCMP-deaminase, 5: inhibition of thymidylate synthase by dFdUMP, 6:inhibition of 
ribonucleotide reductase by dFdCDP, 7: accumulation of the triphophate dFdCTP, 8: incorporation into DNA and 
RNA, 9: inhibition of CTP-synthase by dFdCTP, and 10: dephosphorylaton by 5’-nucleotidase [81] . 
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1.7 Aim of the study 
As mentioned above, PSC plays a very import role in pancreatic cancer’s drug resistance. 
However, no study has ever been done on how PSCs will affect the drug sensitivity of 
different pancreatic cancer cell lines and the exact mechanisms of how PSCs protect tumor 
cells from chemotherapy. That’s the problem what we are going to solve in the current study. 
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2 Materials and Methods 
2.1 Materials 
Table 1 Cell lines 
 
Cell lines Resources 
 
Immortalized PSCs 
 
 
A gift from Ralf Jesnowski [82] , Mannheim Univerisity 
Hospital 
Bxpc-3 Authentificated by DKFZ, Heidelberg, Germany 
Panc-1 Authentificated by DKFZ, Heidelberg, Germany 
Miapaca-2 Authentificated by DKFZ, Heidelberg, Germany 
 
 
Table 2 Antibodies 
 
Product Company Catalogue Number 
Anti-mouse IgG(H+L) Peroxidase Biozol VEC-PI-2000 
Anti-rabbit IgG(H+L) Peroxidase Biozol VEC-PI-1000 
GAPDH Sigma-Aldrich G9295 
RRM1 Abcam Ab137114 
RRM2 Abcam Ab57673 
 
 
Table 3 Kits 
 
Product Company Catalogue Number 
Caspase-Glo 3/7® Assay Promega G8091 
Fast SYBR® Green Master Mix Thermo Scientific 4385612 
Immobilon western chemiluminescent 
HRP substrate 
Millipore WBKLS0500 
RevertAid First strand cDNA synthesis kit Life Technology K1622 
BCA Protein Assay Kit Thermo Scientific 23225 
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Table 4 Reagents 
 
Product Company Catalogue Number 
Chloroform Sigma-Aldrich 288306 
DNase  Thermo scientific EN0523 
Gemcitabine Biomol Cay11690-10 
Isopropanol Sigma-Aldrich W292907 
Lipofectamine 2000 Transfection Reagent Life Technologies 11668027 
Nuclease-free Water Life Technologies AM9939 
Proteinase K Life Technologies EO0419 
Resazurin Fisher Scientific 10684882 
RNase A Life Technologies EN0531 
Spectra Multicolor Broad Range Protein 
Ladder 
Life Technologies 26634 
TRIzol Reagent Invitrogen 15596-018 
Trypsin type I from soybean Sigma T8003 
Trypsin inhibitor type I from soybean Sigma T6522 
RIPA buffer The Geyer 89900 
 
Table 5 Materials 
 
Product Company Catalogue Number 
96 well plate, white (LumiNunc), F96 Fisher Scientific 10072151 
Amicon® Ultra-0.5ml Centrifugal Filters 
Ultracel® -100K 
Merck Millipore UFC510024 
Amicon® Ultra-0.5ml Centrifugal Filters 
Ultracel® -10K 
Merck Millipore UFC505096 
Amicon® Ultra-0.5ml Centrifugal Filters 
Ultracel® -3K 
Merck Millipore UFC500396 
Amicon® Ultra-0.5ml Centrifugal Filters 
Ultracel® -50K 
Merck Millipore UFC505024 
Cell culture plates- 96 well (transparent) DKFZ Lager 655180 
Light Cycler® 480 Multiwell plate 384, 
white 
Roche 04729749001 
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Cell culture plates-6 well (transparent) DKFZ Lager 657160 
Nitrocellulose membrane 0.45µm GE Healthcare GE10600007 
Open-Top Polyallomer centrifuge tubes Scientific service S5030 
 
 
Table 6 Equipments 
 
Name Manufacturer 
NeoBlock1  NEOLAB 
Fluostar Galaxy Plate Reader MTX Lab System 
Mithras LB 940 Multimode Microplate Reader Berthold Technologies 
Sigma 2K15 Micro-centrifuge M&S Labor GERATZ GMBH 
Eppendorf centrifuge 5810R Eppendorf 
Infinite® M200 Microplate Reader 
 
Tecan 
Roller mixers, RS-TR05 Phoenix Instrument 
Beckman L8-M Ultracentriguge Beckman 
Beckmann Rotor SW41Ti 
 
Beckman 
  
2.2 Method 
2.2.1 Cell lines and culture conditions 
Human pancreatic cancer cell lines Panc-1, Miapaca-2 and Bxpc-3 were obtained from 
commercial providers prior to this study. They were all authenticated by DKFZ in-house 
service and tested mycoplasma free before and after the experiments. Immortalized human 
pancreatic stellate cells (PSCs) were a gift from Ralf Jesnowski [82]. They were all routinely 
cultured in IMDM complete medium containing 10% fetal bovine serum, 50 units/mL 
penicillin and 50μg/mL streptomycin at 37 °C with 5% CO2, except Miapaca-2 cultured in 
DMEM complete medium.  
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2.2.2 Gemcitabine cytotoxicity assay 
Analysis of cell growth was used to determine sensitivity of different cell lines to gemcitabine 
in vitro. Briefly, cells were seeded in 96 well plates at 5×10
3
 per well, 24 hours later, serum 
free overnight and then different concentrations of gemcitabine was added. Cells were treated 
with gemcitabine in complete medium for 72h. After that, cell viability was assessed using 
resazurin test.  According to the protocol, resazurin solution was added to each well and make 
sure the final concentration of resazurin is 20µg/ml. Then the plates were incubated at 37°C 
for 2 hours and the fluorescence was recorded using FLUOstar Galaxy system. Ex=544 nm, 
Em=590 nm. The relative viable cells were defined as gemcitabine treated group divided by 
control group.  
2.2.3 Conditioned medium collection  
PSCs were grown in a 175cm
2
 flask to 70%-80% confluence, then the medium were changed 
to serum free IMDM and cells were cultured for another 48h. Medium were collected, 
centrifuged at 3,000×g for 15min and then the supernatant was collected, aliquoted and stored 
at -80 °C until use. 
2.2.3 Apoptosis assay 
Apoptosis of pancreatic cancer cells were tested by commercial Caspase-Glo3/7 Assay kit 
according to the manufacturer’s protocol. Briefly, Bxpc-3, Miapaca-2 and Panc-1 cells were 
seeded in 96-well plates at 8×10
3
 per well, 24 hours later, serum free overnight. Then the cells 
were treated with the following four conditions for 72 hours: a. serum free (SF); b. serum free 
and gemcitabine (SF+G); c. conditioned medium (CM); d. conditioned medium and 
gemcitabine (CM+G). After that, 100µl of Caspase-Glo3/7 Reagent was added to each well. 
The plates were gently mixed on a plate shaker for 30min at room temperature, and a Mithras 
LB940 plate reader was used to measure the luminescence of each sample. 
2.2.4 siRNA transfection 
Two RRM1 siRNAs and two RRM2 siRNAs were bought from Qiagen. Scramble siRNA 
control was purchased from Santa Cruz. Transfection of siRNA was carried out with 
Lipofectamine 2000 according to the manufacturer’s protocol. Briefly, Bxpc-3 cells were 
seeded in a 6 well plate for 24 hours before the transfection, so that they would reach 60%-70% 
confluence when do the transfection. Then 50nM siRNA and 5 µL Lipofectamine 2000 were 
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added to each well, 7 hours later, medium was changed to normal medium. mRNA was 
collected 24 hours post transfection, protein was collected 48 hours after transfection. For 
drug sensitivity assay, cells were collected 48 hours later and seeded in a 96 well plate for 
gemcitabine treatment. The information about the siRNAs used were listed below. 
Table 7 siRNA Information 
 
Product name Target sequence Catalog No. Company 
Hs_RRM1_7  CAGGGCCCATACGAAACCTAT SI03071355 Qiagen 
Hs_RRM1_6 CAGCTACATTGCTGGGACTAA SI03067904 Qiagen 
Hs_RRM2_4 CGGGATTAAACAGTCCTTTAA SI00020790 Qiagen 
Hs_RRM2_3 CACACCATGAATTGTCCGTAA SI00020783 Qiagen 
2.2.5 Real time PCR 
Total RNA was extracted from the cells using Trizol reagent, then 1µg RNA was reverse 
transcribed to cDNA using a commercial reverse transcription kit. Quantitative real time PCR 
were done by using Fast Sybr green and Light Cycler systems, according to the 
manufacturer’s instruction. The primer used were as follows: 
Table 8 Primers 
 
Gene   Primer 
 
RRM1 
 
Forward primer: 5’-CCACTAGCTGCGATGCATGT-3’ 
Reverse primer: 5’-TAGTTCCACTGTGGTGACCC-3’ 
 
RRM2 Forward primer: 5’-CCCTGACTATGCTATCCTGGC-3’ 
Reverse primer: 5’-CCAATGTTGACTTGGCCACC-3’ 
 
Hprt1 Bought from Qiagen   
Product: Hs_HPRT1_1_SG QuantiTect Primer Assay 
Product no.249900 
Cat.no. QT00059066 
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2.2.6 Western blot 
Whole cell lysates were harvested by using RIPA buffer containing protease and phosphatase 
inhibitors. Protein concentration was quantified by BCA kit. 10µg protein was denatured and 
loaded in 12% SDS-PAGE gel and transferred to nitrocellulose membrane. Subsequently, 
membranes were blocked in 5% non-fat milk in Tris-buffered saline (TBS, 10 mM Tris, 10 
mM NaCl) for 1h at room temperature. Then washed and incubated with first antibody 
overnight at 4°C. Secondary antibody conjugated with horseradish peroxidase was incubated 
with the membrane for 1 hour at room temperature. Immunodetections were done with ECL 
(Millipore, US) detection reagent and visualizations were performed by ImageQuant LAS 
4000 mini (Fujifilm Corporation, Japan). 
The primary antibodies used were GAPDH (Sigma, 1:5000), RRM1 (Abcam, 1:10000), 
RRM2 (Abcam, 1:1000). The secondary antibodies used were HRP-conjugated goat-anti-
rabbit (Vector, 1:5000), horse-anti-mouse (Vector, 1:5000). 
2.2.7 Conditioned medium treatment 
In order to find out what in the conditioned medium (CM) is responsible for PSCs-induced 
drug resistance in Bxpc-3 cells, different enzymes were used to digest certain substances in 
the CM. The enzymes and treatment conditions were listed below. For proteinase K treatment, 
CM was incubated with 200µg/ml proteinase K at 37°C for 1 hour. Then certain inhibitor was 
added to neutralize the enzyme. For trypsin treatment, CM was incubated with 200µg/ml 
trypsin at 37°C for 1 hour. Thereafter, it was treated with 400 µg/ml soybean trypsin inhibitor 
at 37°C for 30 min to eliminate the enzyme activity. For heat inactivation, CM was boiled at 
100°C for 2 hour. To eliminate RNAs or DNAs, CM was treated with 100 µg/ml RNase A at 
37°C for 4 hour or 2 U/µL DNase I at 37°C for 4 hour.  
To get rid of exosomes, conditioned media were centrifuged for several steps. First, CM were 
transferred to 50 ml polypropylene centrifuge tubes, centrifuged at 3000 ×g, 4°C for 30min. 
Then the supernatant was transferred to ultracentrifugation tubes, centrifuged at 10,000 ×g 
(7,500 rpm at SW-28), 4°C for 60 min. Thereafter, the supernatant was transferred to new 
ultracentrifugation tubes, centrifuged at 100,000 ×g (28,000 rpm at SW-41), 4°C for 90 min 
and the supernatant was collected. 
Finally, to obtain different fractions of the conditioned medium, the aliquots of the CM were 
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filtered by using Amicon® Ultra-0.5ml Centrifugal filter-3K, Amicon® Ultra-0.5ml 
Centrifugal filter-10K, Amicon® Ultra-0.5ml Centrifugal filter-30K, Amicon® Ultra-0.5ml 
Centrifugal filter-50K and Amicon® Ultra-0.5ml Centrifugal filter-100K. Briefly, according to 
the manufacturer’s instruction, Amicon® Ultra-0.5 devices were inserted into the micro 
centrifuge tubes. Then 500 µl of the conditioned medium was added into each filter. The 
capped filters were spin at 14,000 ×g for 5 min. Subsequently, the Amicon® Ultra-0.5 devices 
were reverse inserted into new micro centrifuge tubes, centrifuged at 1,000 ×g for 2 min. Both 
the media in the filter and out of the filter were collected. Finally, the fractions were 
reconstituted in their original volume-0.5ml by adding serum free media to make sure that 
they have same concentration of active factors. In this way, the fractions we finally got were: 
fractions containing low molecular weight substances (< 3kDa, < 10kDa, < 30kDa, <50kDa, 
<100kDa) and fractions containing high molecular weight substances (> 3kDa, >10kDa, > 
30kDa, >50kDa, >100kDa).  After treatment or fraction, all the media were stored at -80°C 
until use. 
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3 Results 
3.1 Drug sensitivity of different cell lines 
To determine the drug sensitivity, different human pancreatic carcinoma cell lines Bxpc-3, 
Panc-1, Miapaca-2 and PSCs were treated with various concentrations (0.01-100µM) of 
gemcitabine for 72h in complete medium. As shown in Figure 6, for Panc-1, after 
gemcitabine treatment around 65% of the cells was still alive even at the highest 
concentration of gemcitabine. For PSCs, around 48% of the cells were still alive after high 
concentration of gemcitabine treatment. For Miapaca-2, around 35% of the cells were still 
alive after treatment with gemcitabine at the concentration of 100μM. However, with the cell 
line Bxpc-3, only around 10% of the cells were still alive after drug treatment. 
 
Figure 6. Dose-dependent effects of gemcitabine. PSCs and different pancreatic cancer cell lines were treated 
with gemcitabine for 72h in complete medium. Then the viability of cells was detected by resazurin test. Data 
expresses the mean percentage of viable cells of 3 independent experiments. 
3.2 Conditioned medium from PSCs induces drug resistance in Bxpc-3 cells 
In order to find out how PSCs will affect the drug sensitivity of different pancreatic cancer 
cell lines, pancreatic cancer cells were treated with conditioned medium from PSCs together 
with gemcitabine. Results from drug treatment showed that PSCs induce resistance to 
gemcitabine in Bxpc-3 cells, but not in Miapaca-2 cells or Panc-1 cells. As showed in Figure 
7, when Bxpc-3 cells were treated with conditioned medium (CM) and gemcitabine together, 
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more percent of cells were alive compared to the control. For Miapaca-2 and Panc-1, there 
was no difference between control group and conditioned medium treatment group.  
 
Figure 7. Effects of PSCs-CM on the drug sensitivity of different cancer cell lines. The results showed the 
sensitivity of Bxpc-3, Panc-1 and Miapaca-2 cells to gemcitabine in two different conditions: serum free medium 
(SF) and conditioned medium (CM). Cells were treated for 72h. The data represented the mean and SD of three 
independent experiments performed in 8 replicates. *, P<0.001. 
3.3 PSCs secretions don’t reduce gemcitabine-induced apoptosis in pancreatic cancer 
cells 
The apoptosis of pancreatic cancer cells were tested under different treatments by Caspase-
Glo3/7 assay.  As shown in Figure 8A and Figure 8C, no apoptosis differences were observed 
between serum free medium plus gemcitabine (SF+G) treatment groups and conditioned 
medium plus gemcitabine treatments (CM+G) groups both in Bxpc-3 and Panc-1 cells. For 
Miapaca-2 cells, the apoptosis was even increased in CM+ G group (Figure 8B).  
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Figure 8. PSCs secretions don’t reduce gemcitabine-induced apoptosis in pancreatic cancer cells. Pancreatic 
cancer cells were treated with the following conditions for 72 hours: a. serum free (SF); b. serum free and 
gemcitabine (SF+G); c. conditioned medium (CM); d. conditioned medium and gemcitabine (CM+G). Then the 
apoptosis of cells was analyzed by caspase3/7 activity kit. Relative apoptosis of Bxpc-3, Miapaca-2, and Panc1 
treated with the upper conditions were shown separated in A, B, C. The data represented the mean and SD of 
three independent experiments performed in 8 replicates. *, P<0.05.  
3.4 Conditioned medium from PSCs increases RRM1 and RRM2 expression in Bxpc-3 
cells 
As mentioned before, several mechanisms are responsible for drug resistance to gemcitabine, 
such as (1) downregulation of deoxycytidine kinase (dCK), (2) upregulation of cytidine 
deaminase (CDA), (3) upregulation of ribonucleotide reductases, including RRM1 and RRM2. 
Our results showed that conditioned medium from pancreatic stellate cells increased RRM1 
and RRM2 protein expression in Bxpc-3 cells under gemcitabine treatment. 
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Figure 9. Conditioned medium from PSCs increases RRM1 and RRM2 expression in Bxpc3 cells.72 hours after 
the treatment, cell lysate was collected and western blot was used to test the RRM1 and RRM2 protein 
expression in SF+G treated group and CM+G treated group. 
3.5 RMM1 overexpression is required for PSCs-induced drug resistance in Bxpc-3 cells 
To determine whether PSCs-induced drug resistance in Bxpc-3 cells requires the 
overexpression of RRM1, two different siRNAs were used to knock down RRM1 in Bxpc-3 
cells. These two siRNAs reduced RRM1 mRNA expression to 16% and 19% in Bxpc-3 cells, 
respectively compared to control (Figure 10A). The results subsequently led to reduce protein 
expression in Bxpc-3 (Figure 10B). Moreover, drug sensitivity assay results showed that 
PSCs-induced drug resistance in Bxpc-3 cells was no longer existed after RRM1 knock down 
in Bxpc-3 (Figure 10C).  
 
Figure 10. RMM1 overexpression is required for PSCs-induced drug resistance in Bxpc-3 cells. Bxpc-3 cells 
were transfected with control or two different RRM1 siRNAs (50nM) for 24h before determine mRNA 
expression of RRM1 (A), and 48h before determine protein expression of RRM1 (B). C.48 hours after Bxpc-3 
cells transfected with siRNA, cells were serum free overnight and treated with serum free medium or 
conditioned medium for 72h with or without gemcitabine. Then cell viability was tested by resazurin assay. *, 
P<0.05. 
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3.6 RMM2 overexpression plays a role in PSCs-induced drug resistance in Bxpc-3 cells 
To determine whether RRM2 also plays a part in PSCs-induced drug resistance in Bxpc-3 
cells, two different siRNAs were used to knock down RRM2 in Bxpc-3 cells. After 
transfection, the mRNA expressions of RRM2 were reduced to 22% and 25% in Bxpc-3, 
compared to control (Figure 11A). As a consequence, RRM2 protein expression levels were 
decreased (Figure 11B). However, the drug treatment assay results showed that PSCs-induced 
drug resistance in Bxpc-3 was only partially affected by down-regulation of RRM2 in Bxpc-3 
(Figure 11C).  
 
Figure 11. RRM2 overexpression plays a role in PSCs-induced drug resistance in Bxpc-3 cells. Bxpc-3 cells 
were transfected with control or two different RRM2 siRNAs (50nM) for 24h before determine mRNA 
expression of RRM1 (A), and 48h before determine protein expression of RRM1 (B). C.48 hours after Bxpc-3 
cells transfected with siRNA, cells were serum free overnight and treated with serum free medium or 
conditioned medium for 72h with or without gemcitabine. Then cell viability was tested by resazurin assay. All 
experiment were performed in triplicates, and data expressed as mean±SD. **, P<0.001, *, P<0.05. 
3.7 Factor in the conditioned medium is insensitive to enzyme treatments and heat 
inactivation 
In order to find out what in the conditioned medium is responsible for PSCs-induced drug 
resistance in Bxpc-3 cells, conditioned medium was treated with proteinase K, Trypsin, Rnase 
A, or Dnase I before the treatment for Bxpc-3 cells. However, the induced drug resistance 
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effects were still there even after enzyme treatments. And, when conditioned medium was 
boiled at 100°C for 2 hours, the effect was even much higher. Furthermore, when using 
ultracentrifugation to get rid of exosomes, the effect was still there. 
 
Figure 12. Factor in the conditioned medium is insensitive to enzyme treatments and heat inactivation. 
Conditioned media from PSCs were incubated with proteinase K (200µg/mL, 1h, 37°C), trypsin (200µg/mL, 1h, 
37°C), RnaseA (100µg/mL, 4h, 37°C), Dnase I (2U/µl, 4h, 37°C) or heat inactivation (100°C, 2h), the induced 
drug resistance effect of conditioned medium was not reversed. And, when using ultracentrifugation to get rid of 
the exosomes, the effect was still existed. 
3.8 Proteins that have a molecular weight smaller than 100 kDa in the conditioned 
medium are responsible for PSCs-induced drug resistance in Bxpc-3 cells 
To study which fraction in the conditioned medium makes contribution to PSCs-induced drug 
resistance in Bxpc-3 cells, CM was fractioned using Amicon® Ultra-0.5ml Centrifugal filter 
by their molecular weight difference. Totally, 10 different fractions were obtained. These 
fractions were reconstituted in their original volume and used to treat Bxpc-3 cells under 
gemcitabine treatment. As showed in Figure 13, when Bxpc-3 cells were grown in SF 
medium, 0.1μM gemcitabine can kill around 80% of the cells. However, when treated Bxpc-3 
with CM from PSCs, the same concentration of the drug can only kill around 57% of the cells. 
When Bxpc-3 cells were treated with < 3kDa, >3kDa, < 10kDa, >10kDa, < 30kDa, > 30kDa, 
<50kDa and >50kDa fractions, conditioned medium induced drug resistance effects were still 
existed. But, when treated by >100kDa fraction, the CM induced drug resistance effect in 
Bxpc-3 cells was disappeared.  And <100kDa fraction still has the effect. 
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Figure 13. Proteins that have a molecular weight smaller than 100kDa in the conditioned medium are 
responsible for PSCs-induced drug resistance in Bxpc-3. Conditioned medium was fractioned by their molecular 
difference and then used to treat Bxpc-3 cells. Among all the 10 fractions, >100kDa fraction loss the ability to 
induce drug resistance in Bxpc-3 cells. *, P<0.05. 
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4 Discussion 
As mentioned above, patients diagnosed with pancreatic cancer will die within 6 months and 
the survival time of them has not been improved for nearly 40 years. This is due to that 
pancreatic cancer is highly resistant to chemo and radiation therapy. Currently, gemcitabine 
seems to be the most effective drug for pancreatic cancer patients, however, its efficacy is 
limited [73]. The importance of the tumor microenvironment to tumor progression has been 
recognized in recent years and the extensive tumor stromal has been postulated by researchers 
influences tumor response to chemotherapy in pancreatic cancer [60, 83]. However, the 
precise mechanism involved, particularly, how pancreatic stellate cells influence the drug 
sensitivity of pancreatic cancer cells has not been elucidated. In the current study, we chose 
three different drug sensitive pancreatic cancer cell lines, and tested how PSCs will influence 
the chemo-resistance of them. 
There are plenty of pancreatic cancer cell lines exist in the research field of PDAC, Panc-1, 
Miapaca-2 and Bxpc-3 were chose in the current study due to their different drug sensitivity. 
Previous studies have verified that these three cell lines response differently to gemcitabine 
treatment. Such as, Pan [84] proved that Panc-1 and Miapaca-2 are gemcitabine resistant cell 
lines and Bxpc-3 is gemcitabine sensitive cell line. Moreover, Duxbury [85]  found that Panc-
1 and Miapaca-2 cells are more drug resistant than Bxpc-3 cells since their higher expression 
of RRM2. In the current study, same results were obtained, we showed that Panc-1 is the most 
gemcitabine resistant cell line, Miapaca-2 cells are gemcitabine resistant and Bxpc-3 cells are 
gemcitabine sensitive. Besides that, by treating highly activated PSCs with different 
concentration of gemcitabine, we found that activated PSCs are also gemcitabine resistant. 
Stroma influences the drug resistance of pancreatic cancer cells has been shown before. For 
example, Miyamoto [61] found that extracelluar matrix proteins in the stroma are responsible 
for acquired drug resistance of pancreatic cancer cells. Olive [68] discovered that depletion of 
tumor stroma increases the drug response in pancreatic cancer. Hwang [66] confirmed that 
PSCs protect pancreatic cancer cells from chemo and radiation therapy. In our study, we 
observed that PSCs reduce the drug sensitivity of Bxpc-3 cells, but not Panc-1 and Miapaca-2 
cells. That explains why even drug sensitive pancreatic cancer cell lines exist, still no 
pancreatic cancer is curable by drug treatment. It also gives a clue for future personalized 
medicine in the field of pancreatic cancer, targeting PSCs may not work on all patients.  
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Numerous studies have proved that PSC play a crucial role in promoting pancreatic cancer 
cell proliferation [86, 87]. However, no study has shown how PSCs influence the apoptosis of 
pancreatic cancer cells. From our results, we found that conditioned medium from PSCs 
surprisingly increases the apoptosis of all three pancreatic cancer cell lines.  And, when 
treated with gemcitabine, CM from PSCs showed on influence on gemcitabine induced 
apoptosis in Panc-1 and Bxpc-3 cells, but it promote the apoptosis of Miapaca-2 cells. 
Interactions between cells are complicate. Cells may support each other and oppose each 
other at the same time. In the current study, for Miapaca-2 cells, even though PSC enhances 
the apoptosis of them, it has no influence on the drug sensitivity of them. It is possible that the 
induced proliferation effect of PSCs neutralized the apoptosis effect it has on Miapaca-2 cells.  
Since PSCs induce drug resistance in Bxpc-3 cells, the potential mechanism was studied. 
Multiple studies have shown that RRM1 and RRM2 are highly associated with gemcitabine 
resistance. Such as, Fujita [88] found that mRNA expression levels of RRM1 and RRM2 are 
related to gemcitabine sensitivity of patients with pancreatic cancer. Akita [89] discovered 
that after total pancreas resection, patients who can benefit from gemcitabine treatment have 
low expression levels of RRM1. By knocking down RRM2 in several pancreatic cancer cell 
lines, Duxbury [90] found that RRM2 lower expression reduces the invasiveness and 
gemcitabine chemoresistance of pancreatic cancer cells. In the current study, our results for 
the first time showed that conditioned medium from PSCs promotes the drug resistance of 
Bxpc-3 cells through up regulating RRM1 and RRM2. 
Substances exist in the conditioned medium are diverse and plenty, such as, growth factors, 
cytokines, RNA, DNA, biological molecules, exosomes and so on. In an effort to identify 
what in the conditioned medium causes PSCs-induced drug resistance in Bxpc-3 cells, 
conditioned medium was treated with various enzymes. However, the results showed that 
these factors, which we are interested in, are not sensitive to enzyme treatments or heat 
inactivation. Similarly, Jandu [91] studied factors from the conditioned medium of epithelial 
cells and found that those factors that have influences were resistant to proteinase K, trypsin 
and heat treatment. As explained in the article, “proteins can be heat inactivation resistant and 
protease treatment may leave smaller protein behind, the exact molecular identity of the factor 
requires further experiments”. But, Collins’s [92] work about neurite outgrowth verified that 
the influences of heart-cell conditioned medium on neuron is due to some trypsin sensitive 
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factors which bound to the culture substratum. In the current study, we also get rid of the 
influence of the exosomes, but the effect was still there. 
In order to further identify the characteristics of these factors in the conditioned medium, we 
separated the medium according to molecular weight. Totally 10 fractions were obtained, this 
is the first study showed that <100kDa factors are responsible for the PSCs-induced drug 
resistance effect in Bxpc-3 cells. The influence of PSCs’ conditioned medium on the drug 
resistance of Bxpc3-cells maybe is a combined effect, multiple factors make contributions to 
that, so it is difficult to identify one specific substance causative for that. Likewise, Liu [93] 
found that high molecular fractions (>100kDa) from the conditioned medium of human 
oviductal cells improve the development of mouse embryo, but no specific substance was 
identified. Watanabe [94] discovered that >50kDa fractions in the conditioned medium of rat 
epithelial cells increase the growth of neurons, still no particular factor was mentioned. 
In conclusion, our experimental results firstly demonstrated that conditioned medium from 
pancreatic stellate cells promote the drug resistance of Bxpc-3 cells through up-regulating 
RRM1 and RRM2 expression in Bxpc-3, but have no influence on the drug resistance of 
Miapaca-2 cells and Panc-1 cells. Furthermore, we showed the <100kDa factors produced by 
pancreatic stellate cells are responsible for the effects. And these factors are heat insensitive, 
trypsin and proteinase K insensitive, but the exact factor is yet to be determined. 
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